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1. INTRODUCTION 
 
1.1 BREAST CANCER 
 
1.1.1 MAMMARY GLAND 
 
The mammary gland begins to form in the sixth week of fetal development, becoming a complex 
structure in women, relative to men. Its development in women is not complete but it continues to 
change during adolescence and pregnancy. 
The mammary gland is made up by a differentiated parenchyma supported by fibrous scaffold, the 
stroma, surrounded by fatty tissue. The breast glandular tissue is made up of a complex network that 
looks like resembles a bunch of grapes. In adults each breast is composed of about 15 to 20 lobes. 
Each lobe consists of several saccular structures called lobules, which proceed towards the nipple 
through channels called milk ducts, which in turn dilate forming the lactiferous sinuses and 
branching further distally form the terminal ducts. Before puberty this ductal branches system 
ending dead-end, but at the time of menarche is developed resulting in 30 epithelial units, bile or 
berries. Bile-duct with its terminal constitutes the ductal-terminal lobular units. In the female 
puberty begins a branching process stimulated by GH (growth hormone), pituitary, estrogen, 
progesterone, synergistically with IGF-1 (insulin-like growth factor-1) and with EGF (epidermal 
growth factor). Breast reaches its full morphological maturity and maximum functional activity 
only with the pregnancy. Gland is almost exclusively made up of glandular structures separated 
from each other by thin stromal bands at the end of pregnancy. Immediately after giving birth 
begins the secretion of milk and after feeding, the glands undergo atrophy, the ducts are reduced 
and the volume of the breast regresses significantly (Stingl J et al., 2007) (Figure 1). 
 
Figure 1: Breast structure image (National Cancer Institute) 
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1.1.2 EPIDEMIOLOGY 
 
Breast cancer is the most common cancer in women and it is the leading cause of death worldwide. 
It is particularly present in most developed countries, especially America, Australia, Europe, New 
Zealand. In 2008 it was estimated that breast cancer accounts for 23% of all diagnosed cancers and 
14% of all cases of death from cancer (Jemal A et al., 2011; Italian Cancer Registry). Recently, 
there was a new trend concerning the increased incidence of breast cancer even in less developed 
countries. It is estimated that 45% of the 1.35 million new cases diagnosed each year, and more than 
55% of breast cancer related deaths, occur in low and middle income countries (Curado MP et al., 
2007; Porter P, 2008; Tfayli A et al., 2010). 
 
1.1.3 RISK FACTORS 
  
The development of breast cancer has been associated to various risk factors. As previously said, 
the geographic location is an important component for the risk of developing cancer. In 
industrialized countries, the rates of developing cancer are higher than in underdeveloped countries, 
although recently, it seems there is also a rise in those populations (Porter P, 2008). 
The family and genetic component, play an important role in breast cancer development. One or 
more cases of breast cancer in family increase the risk of tumor development, whereas mutations in 
BRCA1 (17q) and BRCA2 (12q) genes correlate with a greater chance of developing cancer within 
70 years. 
Hormonals factors are very important. Several studies have shown that many hormones and growth 
factors are associated with the risk of developing breast cancer. (Key TJ et al., 2003; Kaaks R et al., 
2014). 
Behavioral component is not to be underestimated: alcohol and smoking increase the risk of onset 
of breast cancer (Xue et al., 2011; Key J et al., 2006). Furthermore, it has been shown that a low-fat 
diet reduced 8% the risk of breast cancer (Prentice RL et al., 2006). 
Obesity is to be kept under control especially in the period before and after menopause, probably 
because in the overweight women occur a steroid hormones increased that could lead to a major risk 
of developing cancer (Youlden DR et al., 2012; Colditz GA, et al., 2014; Renehan AG et al., 2008). 
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Finally, women who exercise basic sport activity, are less subject to develop breast cancer (Youlden 
DR et al., 2012). 
 
1.2 CLASSIFICATION OF BREAST CANCER 
 
1.2.1 BENIGN DESEASE 
 
Breast cancer consists of an uncontrolled proliferation of epithelial cells originating from the breast 
ducts or lobules. The tumors are divided into benign and malignant forms, with a greater frequency 
of benign forms. 
Some of benign forms may resemble clinically to malignant forms, while others may be a possible 
risk factors for cancer development. 
The most frequent benign form is fibroadenoma, a fibrous and glandular tissue proliferation, which 
occurs most often in young women (15-30 years). 
The fibroadenoma is characterized by a nodule with a smooth surface and a variable consistency: in 
some cases, can be rubbery; in others, it can be hard; other times, it is described as a highly mobile 
ball. The fibroadenoma can be simple or complex. In the first case, the size and shape remain 
unchanged and over time can reduce its volume. For this reason it doesn’t present a particular 
problem. The complex fibroadenoma, may contain abnormal dense cysts, or calcifications, and 
should therefore be kept under periodical observation. The appearance of fibroadenoma can be 
single, but in some cases may be multiple or bilateral. The causes of fibroadenoma formation, have 
not yet been clarified completely. The origin seems linked to the excessively high levels of 
estrogen. This association explains high incidence of fibroadenoma formation among pregnant and 
young women, where there is a significant amount of circulating estrogen to the body, and the low 
incidence among menopausal and post-menopausal women, where the number of estrogen is 
significantly reduced. 
Intraductal papilloma is another breast benign lesion. It has been found in young and middle-age 
women (35-50 years). It's a very small size mass, formed by fibrous and glandular tissues and blood 
vessels. It is generally formed in the retro-areolar milk ducts that are responsible for secreting milk. 
The most common types are: solitary intraductal papilloma occurs in a mammary duct, usually near 
the nipple; multiple papillomas, appears in the cluster form often in the most peripheral ducts and in 
some cases may evolve into a breast cancer. The intraductal papilloma is one of the most common 
causes of nipple discharge, which overall is found in about 5% of women with breast pathologies. 
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Fibrocystic disease is the most common benign condition. It has been found in 60-90% of women, 
most frequently between 20-40 years. It consists in alterations of morphological mammary tissue, 
such as fibrosis, chronic inflammation, epithelial hyperplasia and the presence of cysts containing 
clear fluid or blood. Normally it is bilateral and involves the breasts widely; but it can also be 
unilateral preferring superior-external area. Its origin is linked to the production of different 
hormones in the various phases of the cycle. It is assumed that there is also a certain glandular 
congenital predisposition, destined to manifest itself in the fertile period, from puberty to 
menopause. 
 
1.2.2 MALIGNANT DESEASE 
 
Breast cancer is divided in histological and molecular classification. The histological classification, 
described morphology (lobules or milk ducts cells alterations), invasiveness (invasive or non-
invasive) and grades or stages of tumor (0 to 5). In the molecular classification, tumor can be 
characterized by hormonal receptors presence. Therefore, we distinguish four different molecular 
subtypes: Luminal A, Luminal B, Triple Negative / Basal-like subtype Her2. 
 
1.2.2.1 HISTOLOGICAL CLASSIFICATION 
 
NON-INVASIVE FORMS 
 
Ductal carcinoma in situ 
 
Ductal carcinoma in situ (DCIS) is a less aggressive non-invasive form of breast cancer. The tumor 
is confined into the duct without invading the surrounding tissues. It can be divided into low (Grade 
1), intermediate (Grade 2) and high (Grade 3) grade. DCIS is categorized according to the growth of 
ductal cells mode: “comedonico”, characterized by irregulars and large cells, with high proliferation 
and necrosis of the duct central part; and "non-comedonico", said also cribriform / micropapillary, 
composed by small and regular cells, free of necrosis. 
If DCIS is not taken care, the confined cells in the duct, can invade surrounding tissues, becoming 
an invasive ductal carcinoma. 
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Lobular carcinoma in situ 
 
The lobular carcinoma in situ (LCIS) is a precancerous: cancer cells grow inside the lobules and 
remain "in situ" and do not extend outside of them. This feature makes LCIS prognosis very good. 
LCIS is more frequent among 40-50 years: in 40-85% of cases is multicentric and in 30% of cases 
is bilateral. It is associated with an invasive form in 5% of patients 
INVASIVE FORMS 
 
Invasive ductal carcinoma 
 
Invasive ductal carcinoma is representing 70-80% of all forms of breast cancer. It originates from 
the milk ducts, then exceeds the duct walls, penetrates in breast adipose tissue and may invade 
surrounding tissues or spread to other parts of the body. 
 
Invasive lobular carcinoma 
 
Invasive lobular carcinoma is representing 10-15% of all forms of breast cancer. It originates from 
the lobules and overcoming the basal membrane, can spread and invade other body areas. It can 
appear simultaneously in several points, either in the same gland, that in both glands. 
 
OTHER FORMS 
 
Medullary carcinoma 
 
Medullary carcinoma is representing for 5% of all breast cancers. It is characterized by a massive 
tumor, with well-defined contours. In most cases there is an abundant lymphocytic infiltration. The 
infiltration intensity has favorable prognostic significance, because it represents an expression of 
tumor host response. 
 
Inflammatory carcinoma 
 
The inflammatory carcinoma is a breast cancer rare form (1-4% of all cancers) and is a fast-growing 
tumor. It may resemble some forms of breast infections (mastitis). Mammary tissue appears red and 
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inflamed, due to the block of breast and skin lymph vessels by cancer cells. Breast changes can 
happen very quickly.  
 
Paget’s desease 
 
Paget's disease is a rare form of breast cancer (<5%) that develops in the ducts cells and spreads to 
the nipple and areola. It has a nipple reddened flaking and may spread to areola, causing itch, sting 
and discharge. It is associated with invasive ductal cancer when there is a lump. This condition 
occurs in approximately half of cases. 
 
Mucinous carcinoma 
 
The mucinous carcinoma, also said colloid, represents about 2% of all breast tumors. The name is 
due to the mucus surrounding the tumor cells. It has a better prognosis and a lower risk of 
metastases. 
 
Tubular carcinoma 
 
Tubular carcinoma is very rare tumor. It represents 2% of all breast cancers and is more common in 
women over 50 years old. It is characterized by the tubular tumor cells presence. It can be 
associated with infiltrating ductal carcinoma or remain pure with a better prognosis. 
 
Cribiform carcinoma 
 
About 4% of breast tumors contain a part cribriforme. It is characterized by gaps between the cells 
that make it look like a sieve. Often the cribriform carcinoma is associated with tubular carcinoma. 
 
Malignant phyllodes tumor 
 
Malignant phyllodes tumor is a rare kind of tumor (<1% of all cancers) that affects women with 40-
50 years not yet in menopause. It appears as a smooth, hard lump that can grow rapidly and also it 
become large. It can present three forms: benign, borderline and malignant. 
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Papillary carcinoma 
 
Papillary carcinoma is a rare kind of tumor, accounting for 1% of all cancers. The cells take on a 
particular fern shape, from which it derives the name. 
 
 
1.2.2.2 MOLECULAR CLASSIFICATION 
 
Breast cancer is characterized by its considerable molecular heterogeneity. The tumor presents 
different mutated genes, whose only some of which are protagonists of the tumor process (Lopez et 
al., 2009). For this reason, patients with identical histologically breast cancer, may have a different 
disease course and a different response to the therapies used. 
Thanks to the use of microarrays (Sorlie T et al., 2001; Sorlie T, 2004), it was possible to classify 
breast cancer at the molecular level. The molecular classification is divided into: 
Luminal A: malignancies with hormone receptors expression, HER2 negative and low proliferative 
activity; 
Luminal B: tumors with hormone receptors expression. It is associated with a high risk of 
recurrence, due to the high proliferative index correlated to high expression of proliferation genes;  
Basal like/ Triple negative: malignancies characterized by the absence of hormone receptors and 
HER2 expressions. It is characterized by a cytokeratin (CK5 / 6 and CK 17) increased expression. 
HER2 subtype: tumor characterized by the presence of HER2 and by increased of genes involved 
in the HER2 expression. 
Thanks to the new pathological and molecular knowledge there is a definition of additional breast 
cancer subtypes. Recently it has been identified, another subgroup of tumors with no expression of 
hormone receptors and HER2, but with markers of stem cells, low expression of claudine (cell-cell 
junction proteins) and lymphocytic infiltrate, called "claudin low" and characterized by poor 
prognosis (Carey LA, 2010; Prat A et al., 2010; Malhotra GK et al., 2010). In addition, gene 
expression analysis of 587 triple negative breast carcinomas has identified six different subtypes 
distinguished by a different molecular biology and a different clinical behavior: basal like 1 e 2 
(BL1 e BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and 
luminal androgen receptor (LAR) (Lehmann BD et al., 2011; Ahn SG et al., 2016). The creation of 
cell lines derived from each subtype has also allowed to show a different sensitivity to 
chemotherapeutic agents and targeted therapies (Carey LA, 2010; Lehmann BD et al., 2011; 
LM_AIOM_MAMMELLA, 2015). 
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2. PAPILLOMAVIRUS 
 
2.1 CLASSIFICATION 
 
Papillomavirus (HPV) is a virus of Papovaviridae family. HPV has been discovered both in human 
and animals. More than 300 HPV have been identified and completeley sequenced, including over 
200 human HPV (Egawa N et., 2015; Van Doorslaer K et al., 2017). HPV is a species-specific virus 
with a high tissue tropism: It has the ability to infect the epidermis and mucosa epithelial tissues, 
generating specific lesions. In this regard, the HPV genotypes were divided into two distinct groups: 
cutaneous and mucosal. The cutaneous HPV are associated with lesions (warts) on the hands and 
feet (1,2 and 4 genotypes), while other HPV genotypes are associated with epidermodysplasia 
verruciforms (5,8,9,12,14,15,17,19-25,36,46 and 47 genotypes). 5 and 8 HPV genotypes are 
associated also with a skin cancer (Cardoso JC et al., 2011; Orth G, 2008; Lazarczyk M et al., 
2009). 
The mucosal HPV, give lesions of the oral, respiratory and anogenital tract. They are divided into 
low and high risk, according to their oncogenic capacity. Among low-risk genotypes, 
6,11,40,42,43,44,54,61,70 and 72 genotypes are classified as a low-risk genotypes, that can lead to 
genital mucosal lesions benign. 16,18, 31, 33, 35, 52, 58, 67 genotypes are considered high risk; 
HPV16 genotype is most frequently associated with cervical cancer (Stoler, 2000). 
The use of phylogenetic algorithms, able to compare multiple genomic sequences, allowed to divide 
HPV genotypes in 37 genera. It was obtained analyzing the sequence homology existing between 
the nucleotide sequences of the L1 ORF region of the genome (Van Doorslaer K, 2013; Bernard 
HU et al., 2010; de Villiers EM et al., 2004). 
Human HPV belong to 5 genera: Alpha, Beta, Gamma, Mu and Nu, which correspond to different 
types having life cycle and disease associations different (Bernard et al.,2010; De Villiers EM et al., 
2004, Van Doorslaer K et al., 2013; Doorbar J et al., 2012) (Figure 2). 
HPV is considered a new genotype when the homology existing between its DNA sequences and 
those of the already classified genotypes not exceed 90%. Viruses with a homology greater than 
90% but less than 98% are defined subtypes and those with a homology between 98% and 100% are 
defined variants (De Villiers EM et al., 2004). 
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Figure 2: HPV genotypes genera (Egawa N et al., 2015) 
 
2.2 GENOME ORGANIZATION 
 
HPV is a circular double-strand DNA virus of about 8000 base pairs with a non-enveloped 
icosahedral capsid. It contains three distinct regions: late (L), early (E) and upstream regulatory 
region (URR) or LCR (long control region). L region includes two genes: L1 (major viral capside) 
and L2 (minor viral capside), which encode structural proteins that are necessary for viral capside 
formation in the final stage of replication. E region contains seven genes expressed in the early 
phase of the replicative cycle, which encode for non-structural proteins, with various regulatory 
functions called E1 to E7. L and E regions are separated by URR, a region of about 1000 base pairs 
that contains a number of cis elements necessary for the regulation of gene expression, DNA 
replication and genome viral encapsidation (Figure 3). 
URR is a non-coding region, as opposed to E and L regions that present open reading frame 
(ORFs). 
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Figure 3: HPV16 genome organitation (C.M. D’Abramo and J. Archambault, 2011) 
 
 
E region: early prtoiens 
 
E1: it is involved in DNA replication and contributes to the maintenance of the genome in episomal 
form. 
E2: it regulates DNA replication and viral transcription through the inhibition of E6 and E7 
proteins. E6 and E7 genes control is lost when the viral genome integrates into the host genome. 
This event lead to suppress, E6 and E7 genes inhibition, which, in turn, act on p53 and pRb, two 
target tumor suppressor genes. 
E4: it is expressed in the late stages of viral infection and is very important in the cellular 
maturation and proliferation. It appears to affect the integrity of the cell cytoskeleton in human 
keratinocytes, determining the koilocytosis, which consists in the deformation of the infected cells 
and subsequent leakage of newly formed viral particles. 
E5: it fits into the infected cell membrane, altering the activity of membrane proteins involved in 
cell proliferation signals (EGF, PDGF); it also downregulates the major histocompatibility complex 
molecules of class I (MHC-I) and inhibits apoptosis. 
E6: this gene degrades p53 by interfering with both its transcription and translation signals and 
apoptosis signals. The interaction with IRF-1 (Interferon Regulatory Factor 1) blocks the genes 
coding for immune proteins transcription induced by IFN and contributes to immune evasion. The 
site of integration is comprised between the 3' of E1 and 5' of E2, resulting in breaking or 
inactivation of E2. The functional loss of E2 results in increased expression of E6. E6 interferes 
with the function of p53 leading to its ubiquitin-dependent degradation that is mediated by the 
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ubiquitin-ligase E6-AP. The functional loss of p53 leads to inactivation of one of the most 
important control systems to avoid genomic instability and the abnormal cell growth. 
E7: it binds the retinoblastoma protein (pRb), which is involved in the regulation of cell growth, in 
cell cycle block and in repression of genes transcription involved in apoptosis. The interaction of E7 
with pRb determines the release of E2F1 protein that, in the absence of E7, is linked to pRb 
hypophosphorylated form. E2F1, can function as transcriptional activator of cellular genes involved 
in the synthesis of cellular DNA and progression in S phase of the cell cycle. In addition, interaction 
with ISGF-3 (Interferon Stimulated Gene Factor 3) and IRF-1 (Interferon Regulatory Factor 1) 
contributes to the innate immune evasion of the virus. 
 
L region: late proteins 
 
L1 and L2 are proteins translated late and are only expressed in productively infected cells. They 
will spontaneously assemble to form the icosahedral capsid. The capsid is composed of 72 
capsomeres. Each capsomere is constituted by a L1 (55 kD pentamer), the major capsid protein, that 
constitutes 80% of the total viral protein. L1 is mainly involved in the binding to the viral DNA, but 
may not incorporate the DNA. It is responsible for the attack of the virus to susceptible cells and 
also mediates the humoral and cell-mediated infection. The capsid of each virion also contains 
about 12 copies of L2 (70 kD), the minor capsid protein (Burd EM, 2003). L2 mainly plays a role in 
structural type, but also in several regulatory functions during the life cycle of HPV, among which 
the bind to the secondary receptors, the determination of the virus nuclear localization and the 
selective DNA encapsidation into the viral capsid, thus increases the virions infectivity (Figure 4). 
 
Figure 4: Function of E and L regions (Egawa et al 2015) 
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2.3 HPV REPLICATIVE CYCLE 
 
The HPV infection takes place through the initial contact of the virus with the surface layer of the 
squamous epithelium multilayered. HPV not encodes a DNA polymerase, but uses a DNA 
polymerase of the cellular host. For this reason, HPV replicates only in the differentiation cells. 
Viral DNA synthesis, capsid proteins production and virions assembly, take place only at the level 
of keratinocytes differentiation terminal process. 
The epidermis is made up of 5 different layers: basal, spinosum, granulosum, lucidum and corneum. 
Corneum layer represent a terminal phase of keratinocyte differentiation, corresponding to a 
specific stage of the viral life cycle. Infection occurs when the virus reaches the basal layer. This is 
made possible by small wounds or abrasions of the host mucosa. The receptors used by the virus to 
make contact with the cells and penetrate inside them have not yet been clearly. It has been difficult 
to study the mechanisms by which HPV enters into the cells and establishes a productive infection, 
because of the difficulty in the production of virus both in vivo and in vitro systems. The interaction 
between HPV and cell surface was therefore investigated using the pseudo-virions formed by 
proteins L1 and L2 self-assemble in heterologous expression systems (VLP: virus-like particles) 
and a reporter plasmid in place of the genome (Touze A et al., 98). 
HPV can bind not only in squamous epithelial cells, but also to other cell types. This indicates that 
the HPV marked tropism for keratinocytes is not due to the receptor specificity (Müller M et al., 
1995). Integrin α6 was the first candidate as a possible receptor HPV, according to studies using the 
VLP (Evander M et al., 1997). VLPs bind to integrin and the use of antibodies directed against α6 
blocks the binding of the virus to the cell. Integrin α6 cooperates with β1 and β4 integrin β subunit, 
located on the cell surface. The α6β1 integrin is expressed on a wide variety of cells, including 
platelets, lymphocytes, endothelial cells, while α6β4 is located on epithelial, mesenchymal and 
neuronal cells. HPV can bind to both integrin types, but preferentially α6β4 profile (Brendle SA et 
al., 2015). These integrins expression is not however necessary for entry of the virus into the cells, 
because some HPV enter into cells lacking these receptors. It has been observed that these viruses, 
bind to heparin and glycosaminoglycans, followed by subsequent receptor binding and 
internalization (Joyce JC et al., 1999; Shafti-Keramat S et al., 2003). 
After receptors binding, the virions enter slowly into the cytoplasmic compartment (Culp TD et al., 
2004), disassemble in lysosomes and then the viral DNA is transferred and transported by the minor 
capsid protein L2 into the core (Day PM et al., 2003). 
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The replicative cycle of the virus can be divided in a non-productive or early stage and a productive, 
or late stage, related to the state of host cell differentiation. 
In the non-productive stage, HPV DNA is maintained in episomal form and early promoter begins 
to express E1 and E2 proteins that trigger the replication of the viral genome. 
In infected basal cells, the DNA is maintained in a low number of episomal copies, about 10-100 
genomes for cell. In this stage, the number of genomic copies remains constant and viral replication 
takes place simultaneously with host cell: the virus uses the structures and the host cellular 
components for the replication of its DNA. 
This type of replication (replication plasmid) allows the virus to establish persistent infection in the 
basal cells of the epidermis, thus inducing a latent infection. A group of these cells leaves the basal 
membrane to stratify and differentiate, making possible the entry of the virus in the epidermis upper 
layers. 
At this level begins the productive stage of the HPV replication cycle that affects the cells of the 
epithelium upper layers (granular layer). These cells are in an advanced differentiation state and 
there isn’t the cellular DNA synthesis, but an intense viral DNA replication is present (vegetative 
replication), with subsequent loss of the genomic copies number control, up to thousands copies for 
cell. It takes place also the late viral gene expression, the capsid proteins synthesis of and virions 
assembly. The complete virus formation will have in the outermost epithelium layer (stratum 
corneum), and the viruses assembled are expelled into the outside environment, when the epithelial 
cells exfoliate. The virions released outside start a new infection (Figure 5). 
 
 
Figure 5: Life cycle organitation during HPV productive infection (Doorbar J, 2005) 
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2.4 HPV AND TRANSFORMATION 
 
HPV is able to generate two types of lesions, high and low. This difference is due to the different 
behavior of the viral genome within the infected cell. The genome of HPV can exist in two states in 
the cellular host: episomal form or integrated into the genome. 
The episomal form is associated with low-grade lesions or cervical intraepithelial neoplasia (CIN) 
and it is associated with the lag phase. The retention of this form is a critical phase of the HPV life 
cycle. The integrated form is highly associated with high-grade lesions and invasive cervical 
carcinoma. It can be integrated in single or multiple copy repeated in tandem.  
The integration appears to occur in fragile sites of human genome, the regions subjected to genomic 
rearrangements and deletions or in the regions directly or indirectly involved in the regulation of 
cell proliferation. To occur integration, the viral genome must go to breaking and then to 
linearization. In this form, there is an interruption of the virus replicative cycle, with subsequent 
destruction of viral genome and cellular genes alterations. There is a loss of the region between E1 
and E2 genes with a consequent non-transcription of the late genes. It is also present an 
uncontrolled transcription of E6 and E7 early genes, which encode for important oncoproteins 
involved in viral replication followed by cellular transformation and immortalization. In tumors 
induced by high-risk HPV genotypes, E1, E6 and E7 genes are integrated and functional, inducing 
cellular proliferation, while the E2, E4 and E5 genes are lost or are not transcripted. 
 
2.5 HPV IMMUNE RESPONSE 
 
The host cell reacts at the entrance of the virus through cooperation between the innate and the 
adaptive immune response. The innate immune response, does not have the characteristic of 
memory but it acts as soon as it notices the presence of pathogens. Its role is crucial for the adaptive 
immune system response, which acts both through more specific response and storing the pathogen. 
The antibodies produced by this system, fight against virus infected cells and allow to prevent 
reinfection. 
The innate immune response is the first system of control, in which are products neutrophils, 
macrophages and lymphocytes subsequently. These agents are activated when the virus enter into 
the cells, due to uptake by toll-like receptor. They detect the presence of L1 and L2 capsid proteins 
and the HPV double-strand DNA. The innate defense system, is activated with the production of 
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various inflammatory cytokines, such as IL-1 beta, IL-6, IL-8, IL-12 and interferon alpha, beta and 
gamma, which in turn activate natural killer cells and other immune system cells (Woodworth, 
2002). The second phase of immune system, consists in the adaptive immune response. In this 
phase, the antigen-presenting cells (APC), such as Langerhans cells or dendritic cells (DC), process 
the viral antigens into small peptides that are presented together with MHC to lymphocytes. DCs 
migrate into the lymph nodes, where happens the maturation process. The complex of viral antigen / 
MHC present on DCs cells, binds to specific cell receptors CD4 + and CD8 +. This binding induces 
T cells proliferation and activation. The activated CD4 + cells can differentiate into Th1, Th2 or 
Treg / Th3, that produce different cytokines: Th1 cells produce IL2, IL12, IL15, and TNFalpha; 
Th2 cells produce IL4, IL5, IL6, IL10 and IL13; Th3 cells produce IL10, TGFbeta and INFgamma. 
(Rosales R et al., 2014). The activated CD8 + cells can differentiate into cytotoxic T lymphocytes 
(CTL) that produce different types of enzymes. In addition, the CTLs can migrate to the site of 
infection and destroy cells infected by HPV. The adaptive immune response is therefore very 
important and effective in most cases. It includes two types of responses: humoral and cell-
mediated (Figure 6). 
 
Figure 6:  Cellular immune response against HPV (Rosales R, 2014) 
 
Humoral Response 
 
The humoral immune response is more prevalent in patients with an HPV infection, and you can 
detect it with the presence of antibodies against the L1 and L2 capsid proteins and E4, especially in 
the early stages infection. Antibodies against E6 and E7 can be identified in the later stages, when 
the virus is integrated into the cellular genome, especially in low and high-risk lesions. The mature 
B cells release antigen-specific antibodies, in order to block the virus entry and to prevent new 
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infections. The circulating antibody, can opsonize and agglutinate the viral particles and facilitate 
phagocytosis by macrophages. The antibody response is often weak and variable and does not seem 
to be protective for future infections. The humoral response, does not seem to be efficient to 
eliminate the persistent infection of HPV. In any case, the antibodies remain for a long time, even 
when the virus has been eradicated, so their measurement can be used to evaluate a past infection. 
 
Cell-mediated response 
 
The cell-mediated response is most effective against the HPV lesions. The T CD4 + and CD8 + 
lymphocytes are produced to eliminate infected cells. Patients that have eliminated HPV infections, 
have high levels of viral proteins, CD4 and CD8 circulating. A high ratio of CD4 and CD8 with a 
predominance of Th1 cytokines are observed in the lesion regression phase. Conversely, a low ratio 
of CD4 and CD8 and an increase in Th2 cytokines are observed and associated with persistent 
injuries. The cell-mediated response is very important for the elimination of HPV lesions. 
 
2.6 ESCAPE THE IMMUNE RESPONSE 
 
HPV infections are not easily recognized by immune system. The HPV, especially high risk 
genotype, have developed systems to evade the immune response of the target cell. HPV is not a 
cytopathic virus, but is an epithelium-tropic virus, that infects the basal cells of the epidermis and 
thanks to the differentiation of keratinocytes, the HPV infected cells arrive to the epithelial surface 
and become infectious. 
This system lead to a viraemic phase lack and inflammation and an absence of pro-inflammatory 
cytokines production. The proteins oncogene E6 and E7, are able to downregulate the interferon 
pathway, through the inactivation of the INF alpha genes (Zivadinović R et al., 2014). E7 protein, 
increases the IL-18BP production, an anti-inflammatory cytokine, which mediates the activation of 
CD4 + T cells, causing their reduction (Richards KH et al., 2014). Finally, HPV reduces and alters 
the signals that lead to dendritic cells activation and migration, the MHC- I migration and APC. 
 
 
 
 
21 
 
2.7 VACCINES 
 
Prophylactic vaccination anti-HPV 
 
In the last few years, vaccines have been developed for certain genotypes. In particular, HPV16 and 
HPV 18 infections in high-grade lesions and frequent HPV6 and HPV11 detection in genital warts, 
have led to the formulation of two kinds of vaccines, both derived from virus-like particles (VLP) 
produced by recombinant technology. They do not contain any living biological product or DNA, 
and they are not infectious viral particles (Cutts FT et al., 2007). They have the ability to induce a 
protective immune response specific type. The bivalent vaccine, Cervarix (GlaxoSmithKline), 
contains VLPs for HPV16 and HPV18 types (total associated with about 70% of all cervical 
carcinomas). The quadrivalent vaccine, Gardasil® (Sanofi Pasteur MSD), contains VLPs which 
prevents lesions caused by four types of the virus: HPV 6 and HPV 11 (responsible for 90% of 
genital warts), in addition to HPV 16 and HPV 18 (formerly treated by bivalent). 
Italy was the first European country to schedule a public vaccination strategy against the HPV virus, 
in particular the Agency for Drug Agency (AIFA) and the National Health Council saw fit to free 
vaccinate all girls with eleventh year of age (http://www.salute.gov.it). 
It has been shown that 99% of vaccinated women developed antibodies and higher antibody levels 
are achieved in girls vaccinated between 9 and 13 years compared to those vaccinated between 16 
and 26 years (Italian journal of public health, QIJPH-2014). 
The efficacy of the quadrivalent vaccine to preventing cervical cancer and warts, evaluated on a 
population of 18.000 women, was 95-100% (FUTURE II Study Group., 2007). The effectiveness of 
the divalent form is around 90% (Cutts FT et al., 2007). This type of strategy, targeted to 
vaccination of not sexually active adolescents that do not come into contact with the virus, it can be 
definitely an advantage for prevention; In this regard it is evaluating the effectiveness of the vaccine 
also of sexually active adolescents (Villa LL, 2007).  
A second generation of anti-HPV vaccine was approved by the FDA in December 2014. It is a 
ninth-valent vaccine (HPV9) that provides protection for the same types of HPV4 (quadrivalent) 
with the addition of five HPV genotypes (31, 33, 45, 52 and 58). HPV9 provides protection against 
the 80% -90% of cervical tumors, about 10% -20% more than the vaccines approved previously and 
has been shown to be safe and effective (Fontenot HB et al., 2015). 
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Therapeutic vaccins 
 
During these last years, it is developing a therapeutic vaccine type targeted to induction of a cell-
mediated immune response specific to particular tumor antigens, such as E2, E6 or E7. 
This type of vaccine would be aimed to all women who have a persistent infection and are generally 
not helped by a prophylactic vaccine, to the men and women susceptible to HPV infections in other 
locations, including oral cavity and the anus and towards countries where it is still high mortality 
from cervical cancer. At present, are under study five different methodologies, based on the 
administration of antigenic peptides or recombinant proteins, viral vectors and presenting dendritic 
cells as antigen E7 or E6. The results of clinical trials are not yet clear, but in some cases seem to 
give good results (Nonn M et al., 2003; Ferrara A et al., 2003). 
 
2.8 CLINICAL MANIFESTATION FROM HPV 
 
HPV may give to different types of clinical manifestations, depending on the affected anatomical 
region. HPV can infect skin, generating both benign events, with formations of warts on the back of 
the hand, feet or face, and malignant events, such as the onset of skin cancers. A mucosal level, 
HPV infection may give rise benign manifestations, with the formation of male and female genitalia 
warts and lesions in aerodigestive tract. Especially, the uterine cervix, respiratory and anogenital 
tract are subjected to a mucosal malignant transformation. 
 
2.8.1 Hpv and Breast Cancer 
 
Over the past 25 years, several studies have attempted to relate HPV with breast cancer. In 1990, it 
was described and demonstrated that HPV can immortalize human mammary epithelial cells (Band 
V et al., 1990). In 1992, a study described the presence of HPV16 in 29% of breast tumors and 
metastatic lymph nodes (Di Leonardo A et al., 1992) and later was described a relationship between 
breast and cervical cancer tissues, where it was identified HPV16 (Hennig EM et al., 1999). 
In patients with breast cancer, HPV has been associated with very different populations, especially 
the 16, 18 and 33 high-risk genotypes (Amarante MK et al., 2009). 
Identify HPV in breast cancer is very difficult, due to the low viral load of virus present in breast 
tissue (Herrera-Romano L et al., 2012), and the low-sensitive techniques to detect it. Despite these 
difficulties, the HPV sequences have now been identified in mammary tumors in several studies. 
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Recently meta-analysis study was conducted on 22 case-control studies. 2845 samples were 
analyzed, including 1897 cases of breast cancer and 948 controls. The results indicate that HPV 
infection is associated with an increased risk of developing breast cancer, compared to controls 
(odds ratio 4.2) (Bae JM et al., 2016). 
It has been shown that the prevalence of HPV high-risk is high in early breast cancer as compared 
to late breast cancer, and it is due to the HPV action on the APOBEC3B pathway (Ohba et al., 
2014; Vieira VC et al., 2014). 
Finally, it was observed that women with an HPV positive cervical disease, can develop, HPV 
positive breast cancers and these women are subject to a greater risk of developing this type of 
tumor (Lawson JC et al., 2016). 
The role of HPV in breast cancer, appears to be of great interest. On the basis of the data reported in 
literature, it seems that it can influence the development of cancer, increasing the risk of occurrence, 
but it remains to clarify the way through which it reaches the breast tissue. 
 
2.8.2 Hpv and uterine cervix 
 
It was observed and described that some HPV genotypes, are associated with the onset of the 
uterine cervix cancer and are particularly interested squamous cells (80 -90%) (Burd EM 2003). 
Usually, when the genital infection is subclinical, it doesn’t cause injury but it resolves 
spontaneously (SIL). Otherwise, the infection can progress and generate low-grade intraepithelial 
lesions (LSIL). The LSIL may regress spontaneously or persist and progress to squamous 
intraepithelial lesions of high grade (HSIL) and carcinoma in situ. It is possible to classify cervical 
cancer at histopathological level, depending on the change and degree of injury: CIN1, is 
characterized by episomal viral DNA form and by E6 and E7 expression gene relatively low 
(Schiller JT et al., 2010); CIN2, is characterized by the presence of both episomal and integrated 
viral DNA form. In this phase, cells that have integrated viral DNA, overexpress the viral proteins, 
which lead to an increase of cell proliferation and degree of malignancy. At this point the lesion 
evolves towards CIN3, characterized by keratinocytes which lost the ability to regulate the 
proliferation and cell differentiation, and gained the ability to uncontrollably express E6 and E7 
oncoproteins. (Stanley M, 2003). The only infection from HPV high risk is necessary, but not 
sufficient to trigger the tumor progression. Other host and environmental factors, including genetic 
and epigenetic events are required to induce tumor progression. (Zur Hausen H, 2002). 
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2.8.3 Hpv and oral cancer 
 
Although the majority of cervical cancers are caused by HPV, there is a small portion of the non-
cervical tumors, including oral cancer, which undergo to HPV infection (Kim SM, 2016). Oral 
cancer is classified as head and neck cancers (HNSCC). Unlike HNSCC, in which the causes appear 
to be due primarily to alcohol and smoking, recently, oral cancer has been associated with HPV 
infection, in particular the 16 genotype. (Sun JR, 2012; Gillison ML et al., 2008). There was a 
significant association between HPV infection, oral squamous cell carcinoma and, although 
variably, malignant oral cavity lesions, such as leukoplakia and erythrocyte erythroplakia. 
(Pierangeli A et al., 2016). This type of cancer, occurs mainly to tonsillar level, on the base of 
tongue and on the soft palate and mostly affects people under 50 years old. This disease is 
transmitted sexually and by skin contact, so, the frequent change of partners without using 
precautions, oral sex with people with HPV positive genitals infections and the first sexual 
experience at an early aged, can be factors predisposing to the onset of HPV infection and tumor 
(Heck JE et al., 2010). 
 
2.8.4 Hpv and colon 
 
The pathology of colorectal cancer is considered a multifactorial disease: the carcinogenesis model, 
shows a progressive accumulation of genetic damage, which can lead to polyps formation and 
subsequent evolution in cancer. A small portion of cases is characterized by genetic predispositions, 
while in the others cases are well described the external factors, such as lifestyle, a sedentary 
lifestyle, abuse of alcohol and red meat, a high fat-diet and low fiber-diet or biological agents, 
although the molecular mechanisms are not yet completely understood (Perez LO et al., 2010; Beart 
RW et al., 1995; Gazelle GS et al., 2000; Vainio H et al., 2003). 
Kirgan et al (1990), described a potential association between HPV and colorectal cancer. Recently, 
several studies have been reported, HPV and the risk of tumor (Yavuzer D et al., 2011; Lorenzon L 
et al.,2011; Giuliani L et al., 2008). HPV infection in colorectal cancer could be due to an infection 
coming from anogenital sites (Perez LO et al., 2005) or through blood and lymphatic circulation 
(Chen TH et al., 2012; Chen AC et al., 2009). Other studies report an association with sexual and 
behavioral habits (Veldhuijzen NJ et al., 2010). However, the meta-analysis studies conducted in 
recent years (Damin DC et al., 2013; Baandrup L et al., 2014; Pelizzer T et al., 2016), suggests an 
important role of HPV in colorectal cancer, since it is considered a possible co-factor for the 
development of diseases. 
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3. POLYOMAVIRUS 
 
The polyomavirus family is composed by a DNA non-enveloped viruses of about 5000 bp, that 
infect a large number of vertebrates, including humans, primates, mice, rabbits, and many species of 
birds. (Imperiale MJ, 2001; Delbue S et al., 2012). Capsid is composed by three viral proteins 
designated VP1, VP2 and VP3. Viral genome has a similar organization between the various virus 
and presents highly conserved regions. The first human polyomavirus, were identified in the 1970 
and their names are derived from the initials of the subjects in which they were identified: JC (JCV) 
was found in patient brain with Hodgkin's disease and progressive multifocal leukoencephalopathy 
(PML) (Padgett BL et al., 1971); BK (BKV) was found in the urine of a renal transplant (Gardner 
SD et al., 1971). In recent years were found and described other viruses: in 2007 were found the 
polyomavirus KI (Karolinska Institutet) and WU (Washington University) in airway samples from 
patients with lung disease, also known by the initials of patients who were identified (Allander T et 
al., 2007; Gaynor AM et al., 2007); in 2008 the Merkel Cell virus, was found in > 80% of the 
samples of Merkel cell carcinoma, rare neuroendocrine tumor of the skin, but also in samples of 
numerous other tissues from healthy individuals affected by different pathologies (Feng H et al., 
2008); in 2010 the 5 and 6 polyomavirus (PyV5 and PyV6) were detected in skin samples 
(Schowalter RM et al., 2010) and Trichodysplasia spinulosa virus (TSV) was associated to the 
homonym and follicular rare inflammatory skin disease seen in patients deeply 
immunocompromised such as organ transplant recipients (van der Meijden E et al., 2010) . In 
human samples there were also detected even primate polyomavirus: in particular, Simian Virus 40 
(SV40) was introduced in humans with the use of anti-polio vaccines in the 60s prepared on cell 
cultures of infected monkey; the Lymphoptropic Polyomavirus, for which it seems a relatively high 
frequency (15%) of exposure on the basis of epidemiological data serum (Kean JM et al., 2009). 
SV40 was also found in people who do not was administered polio vaccine, so this leads to the 
assumption that the propagation has happened not only by immunization, but also to vertical and / 
or horizontal transmission (Shah KV, 1972). It was also associated with human neoplastic diseases, 
but without some evidence because frequent plasmid detectable contamination in laboratories 
around the world. Although the sequences of Polyomavirus are highly conserved, they have a 
restricted host range: they productively infect permissive cells and lead to neoplastic transformation 
of non-permissive cells, generating different malignancies. The oncogenic transformation is 
mediated by early proteins, called antigens T, who manage to cross the cell cycle controls and 
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replicate efficiently. The Polyomavirus establish a primary infection, typically latent, which tends to 
be associated with a symptomatic clinical picture only under certain conditions. 
 
3.1 POLYOMAVIRUS STRUCTURE 
 
The polyomavirus are small circular double-stranded DNA viruses of about 5000 bp, without 
enveloped, with an icosahedral capsid of 45 nm. The capsids are composed of three viral proteins 
(VP1, VP2, VP3) that surrounding the DNA assembled in the form of chromatin with H2A, H2B, 
H3 and H4, cellular histones. This complex is often called minichromosome. The capsid proteins 
are organized to form an icosahedral capsid of 360 molecules of the major capsid protein VP1, 
organized in 72 pentameric capsomeres. The VP2 and VP3 protein (minor capsid protein) are 
associated with each pentamer.  
 
3.2 POLYOMAVIRUS GENOME 
 
The genome of all polyomavirus is about 5000 bp and is divided into three regions: precocious 
(early), late (late), and regulatory expertise. (Cole and Cozen, 2001). In the early region are 
expressed a set of multifunctional regulatory proteins, tumor antigens (T / t), immediately after the 
entry of the virus into the cell and continue to be expressed, after infection and the onset of viral 
replication. Genetic and biochemical analysis of the SV40 T antigen and MPyV revealed that the 
large T antigen (TAg) is essential to drive the infected cells in quiescent phase to the S phase of the 
cell cycle, to initiate and complete replication viral DNA and to promote the virion assembly (Ahuja 
D et al., 2005). In the late stage, the three capsid proteins are expressed (VP1, VP2 and VP3) and 
even in some cases an agnoproteina, so called because of its unknown function: it seems that 
facilitate nuclear localization of the VP1 protein and promotes the assembly of viral particles and 
the subsequent spread of the virus from cell to cell. The regulatory region (RR) is located between 
the early and late transcriptional unit and contains a bidirectional enhancer, promoters for the early 
and late region, the origin of viral DNA replication and the signal for the assembly of virion (Figure 
7). 
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Figure 7: Scheme of a prototype PyV genome (Tina Dalianis and Hans H. Hirsch, 2013) 
 
3.3 REPLICATION CYCLE 
 
The viral replication begins after virus adsorption in the host cell. The virus enters into the cell and 
is transported directly into the nucleus, where it is released and made available to begin the 
transcription of the early viral genes through the host cell transcriptional apparatus operates. The 
primary transcript of the early region undergoes alternative splicing and leads to the formation of 
multifunctional regulatory proteins (small and large T). The antigens T stimulate cells to produce 
enzymes necessary for the replication of cellular DNA, thus preparing the cell to viral DNA 
replication. The late viral genes are then expressed and they code for capsid proteins. In this step, 
there is a new virions assembly in the nucleus of infected cells and release of the virus, probably at 
the time of cell death. 
 
3.3 SV40 
 
SV40 was isolated for the first time in 1960 from a monkey kidney to produce the polio vaccine. In 
animals were observed different modes of virus transmission through urine and respiratory route 
(Horvath CJ et al., 1992) and also were observed tumorigenic properties (Eddy BE et al., 1962; 
Diamandopoulos GT, 1972; Vilchez RA et al., 2003). Because of the accidental administration of 
the polio vaccine in humans (1955-1963), this virus has aroused particular interest to understand its 
functionality in tumors. DNA sequences similar to those of SV40 have been found in a wide variety 
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of human tumors, such as, for example, choroid plexus tumors (Lednický JA et al., 1995) 
medulloblastomas (Huang H et al., 1999) and in bone tumors (Carbone M et al., 1996) where SV40 
DNA sequences were found in 40-50% of mesotheliomas, albeit variably in relation to geographical 
areas (Emri S et al., 2000). Numerous studies raise many concerns, because most of human cancers 
associated with SV40, correlate with the tumors observed in experimental animal models. 
There are different methods to detect SV40, but the obtained results are still not clear. It remains to 
be seen whether the virus could significantly contribute to the onset disease or whether it can 
increase a compromised condition and if in some cases, the pathologic microenvironment, may 
provide a trigger to reactivate a latent SV40 infection (Figure 8). 
 
 
Figure 8: SV40 genomic DNA (Ahuja et al., 2005) 
 
4. EXTRA-CELLULAR VESICLES 
 
In recent years, it has been suggested a cell-cell communication mechanism, mediated by 
extracellular vesicles. The extracellular vesicles are released from different types of cells, tissue and 
biological fluids and poured into the extracellular environment. They are divided according to 
different criteria: sizes (microparticles, microvesicles, nanovescicole and nanoparticles); type of cell 
or tissue origin (prostasoma and oncosoma); functions (calcifying matrix vesicles, argosomes, 
tolerosomes) and their presence outside cells (ectosoma, exosome complex, esovescicole, exosome-
like vesicles) (Colombo M et al., 2014). 
29 
 
Although it was already described the release of apoptotic bodies during the process of apoptosis 
(Hristov et al., 2014), the release of vesicles by properly functioning cells was described only in 
recent years. In particular, microvesicles, ectosomi, shedding vesicle and exosomes are described 
(Gyorgy et al., 2014). Ectosomi, shedding vesicle, microparticles and microvesicles, are contained 
within a range from 150-1000 nm, while the exosomes have a size between 30-150 nm. Despite 
differences in terms of size, composition, morphology and density, it is difficult to distinguish 
exosomes from the microvesicles group (Bobrie A et al., 2011).  
 
 
4.1 EXOSOMES 
 
In 1970, it was described vesicles enclosed by a membrane, made by different types of tissues, cells 
and biological fluids (Anderson HC 1969; Trams EG 1981; Dvorak AM  1981). In 1980, it was 
described a more complex pathway of microvesicles secretion, which provided for the release of 
vesicles formed within multivesicular endosomes (MVB) (Pan BT et al., 1985). The term 
“exosome” appears in the following years, when the Dott. Johnstone described them as small 
membrane vesicles, released from the MVB system, during the development of reticulocytes, whose 
job was to clean the cellular waste from the cytoplasm during reticulocytes maturation (Johnstone 
RM, 1987). For several years, exosomes have assumed a marginal role until the end of the 90s, 
when their potential importance as mediators in intracellular communication was described (Raposo 
G et al., 1996; Zitvogel L et al., 1998). Exosomes secreted by Epstein-Barr virus (EBV) -
transformed B cell lines containing MHC II (Raposo G et al., 1996) and exosomes produced by B 
lymphocytes in vitro were able to stimulate the response mediated by T cells (Zitvogel L et al., 
1998). The hypothesis of exosomes as mediators of the immune response and intracellular 
communication, led to further investigation about their functions. 
In recent years, several studies describe the role of exosomes: has been observed their role in cell-
cell and distance communication, interacting with the recipient cells (Lo Cicero A et al., 2015). It 
was highlighted their contribution in tumor progression by promoting angiogenesis and metastatic 
tumor cell migration (Rak J, 2010; Hood JL et al., 2011; Peinado et al., 2012); it was also noted 
their inactivators  role of immune response (Zhang HG and Grizzle WE et al., 2011).  
Exosomes are secreted in both pathological and physiological condition from numerous types of 
cells, such as dendritic, hematopoietic, epithelial, nervous system, fibroblasts and cancer cells. Their 
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production increased in stress condition, for example, temperature or ph of membrane changing, 
hypoxia, oxidative stress, viral infections and radiation. 
Exosomes are composed of many molecules. There is a database, which describes all the 
microRNA, mRNA, and proteins found in these vesicles. From the analysis of 146 studies were 
identified and associated with the exosomes, 13333 proteins, 2375 mRNAs and 764 miRNAs 
(www.exocarta.org). RNA and microRNA were the first to have been found and described in 
exosomes (Valadi et al., 2007) and they have been studied to understand their functionality (Skog J 
et al., 2008). Early studies of proteomics, showed that the exosomes contain specific cellular 
proteins content, some of which depend on the cell type from which they come. To date the 
exosomes are constituted mainly by endosome, cytosol and membrane proteins, and to a lesser 
extent by nucleus, mitochondria, endoplasmic reticulum and Golgi apparatus proteins (Colombo et 
al., 2014). It was also analyzed the lipid content, observing a prevalence of fatty acids, 
sphingomyelin, posphotidilcholine, ceramide and cholesterol (Laulagnier et al., 2004; Llorente et 
al., 2013; Trajkovic et al., 2008). The contents of exosomes are also enriched by DNA (Jin Cai 
2016), viral nucleic acids (Gould et al., 2003; Laganà et al., 2013; Hoen et al., 2016), 
transmembrane, fusion, cytoskeleton and membrane transport proteins, enzymes, signal 
transduction, adhesion molecules and antigen presenting molecules (Colombo et al., 2014). How 
exosomes exert their functions is not yet entirely clear. (Figure 9) 
 
Figure 9: Schematic representation of exosomes composition (Colombo M et al.,, 2014) 
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4.2 BIOGENESIS OF EXOSOMES 
 
Exosomes originate from the endosomal system, which generates the different intraluminal vesicles, 
that are direct in the right directions: some of them can expect degraded by the lysosomal system, 
while others will face recycling or exocytosis. Endosomes are divided into three compartments: 
early, late and recycling. Early endosomes fuse with endocytic vesicles and incorporate their 
content, which can be recycled, degraded or esocitated. The vesicles destined for recycling, are 
directed to the recycling compartment, while the remaining early endosome, with its content, 
undergoes a series of transformations and becomes late. During this process, the endosomal content, 
is divided into many small vesicles of 30-100 nm (ILVs), which fuse directly with the lumen of late 
endosome and are called multi-vescicular body (MVBs). Late endosomes can fuse with the 
lysosome resulting in destruction of the endosomal content, or can fuse with the plasma membrane, 
followed by vesicles secretion in the extracellular space. These vesicles are called exosomes. They 
can reach the target cells in different ways: they can attach and fuse with the membrane cell, 
releasing their contents, or can be endocitate and then fuse with the membrane of a cell 
compartment, pouring their material (Raposo G et al., 2014). 
Exosomes can be characterized at the molecular level, thanks to the presence of certain proteins 
features, which appear to result from the process of ILVs formation. 
The ILVs would be formed through the triggering of two different processes. In the first, the 
endosome membrane, forms a specialized region, rich of tetraspanine, a class of membrane proteins 
(Pols MS et al., 2009). The tetraspanine consist of four transmembrane domains, interconnected by 
variable sequences, that enhance cell-cell specific binding. CD9 and CD63 are two tetraspanine that 
seem to be involved in the formation of exosomes and they are used as markers for exosomes 
characterization and isolation (Jansen FH et al., 2009; Kosaka N et al., 2010). 
The second process involves approximately thirty proteins that assemble each other and form 4 
complex, called endosomal sorting complexes required for transport (ESCRT 0, I, II, III) (Wollert T 
et al., 2010; Hurley JH, 2010; Babst M et al., 2002). ESCRT 0 has the duty to recognize and seize 
the ubiquinate transmembrane proteins in the endosomal membrane; ESCRT I and II are 
responsible for membrane deformation into buds, while the ESCRT III, is responsible for the 
membrane formation and the ILVs cleavage. The recruitment of ESCRT III takes place through 
Alix, a protein that binds simultaneously TSG101, ESCRT I component, and CHMP4, ESCRT III 
component. Tsg101 and Alix are two proteins used for exosomes characterization (Wollert T et al., 
2010; McCullough J et al., 2008; Akers JC et al., 2013).  
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The way through which the exosomes are internalized by receiving cells, has not yet been 
completely clarified. It is assumed that the exosomes may enter into target cell, through simple 
fusion with host cell membrane, releasing their contents directly into the cytoplasm; through 
endocytosis, or due to the presence of specific receptors that allow exosomes-recipient cell binding 
(Gajos-Michniewicz A et al., 2014). The cells from which exosome originate, are decisive both for 
exosomes superficial contents formation and to address them towards the appropriate recipient cell 
(Taylor DD et al.,2013). A single exosome presents different adhesion molecules on its surface and 
it is capable to bind different cell surface receptors (Record M et al., 2014) (Figure 10). 
 
 
Figure 10: Formation and release of exosomes (Junker K, 2016). 
 
 
4.3 EXOSOMES AND TUMORS 
 
Tumor is a multistep process that involves several microenvironment changes, resulting in 
uncontrolled cell proliferation. The tumor microenvironment undergoes changes due to cancer cells 
genetic instability and the induction of some factors, such as cytokine and immune cells increased, 
inflammatory response, promotion of angiogenesis, cell migration and invasion, hypoxia 
environment. 
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Several studies describe the release of exosomes by tumor cells, which appear to be involved in 
normal cancer cell-to-cell communication and contribute with other factors to the progression and 
maturation of the tumor microenvironment. The role of exosomes has been deepened in different 
types of tumors (Kharaziha P et al., 2012).  
Exosomes are increased in patients with cancer, due to a greater release by tumor cells, and their 
increased expression seems to correlate with a greater tumor size (Logozzi M et al., 2009). 
Exosomes are involved in cell invasiveness, since they are capable to change stromal cell, 
remodeling extracellular matrix and stimulating angiogenesis, especially exosomes released in 
hypoxic conditions (Katoh M, 2013; Khalyfa A et al., 2016). Exosomes play a role in tumor cell 
migration and in the acquisition of invasive properties in non-cancerous cells (Epple LM et al., 
2012; Xiao et al., 2012).   
The exosomes would seem to contribute to the formation of pre-metastatic niches, through the 
transport of biological molecules necessary to metastatic process (metalloproteases, angiogenesis 
factors, tetraspanin), and promoting the migration and tumor cells invasion (Fleming A et al., 2014). 
The formation of the pre-metastatic niches is a fundamental requirement, for tumor metastases. It 
was shown that melanoma metastases, uses the way of the MET receptor to modify the 
characteristic phenotype of progenitor bone marrow cells, in a pro-angiogenic and pro-metastatic 
phenotype (Peinado H et al., 2012). It has also been described that exosomes released by stromal 
cells of a gastrointestinal tumor, manage to convert the smooth muscle cells in a pre-metastatic 
sense (Atay S et al., 2014). The direct involvement of exosomes released by metastatic cancer cells 
was observed in vitro and in vivo through the use of imaging fluorescence methods (Suetsugu A et 
al., 2013). 
Exosomes appear to play a very important role in the development of a tumor (Figure 11). 
 
 
Figure 11: Role of exosomes in tumor microenviroment (Roma-Rodrigues C, 2014) 
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4.4 EXOSOMES AND IMMUNE SYSTEM 
 
The exosomes produced by cancer cells, seem to be able to inhibit the immune system cells 
function. It has been reported that exosomes produced by human prostate cancer cells, 
downregulate NK and CD8 + T cells expression, block the differentiation of murine myeloid 
precursor cells into dendritic cells (Yu S et al., 2007) and decrease the number and function of 
antigen presenting cells (APC) (Lundholm L et al., 2014; Yu S et al., 2007; Berchem G et al., 
2015). 
On the other hand, it was also described the role of exosomes in immune response. The presence of 
tumor antigens, has been exploited to stimulate dendritic cells, inducing CD8 + T cell and 
increasing immune response (Bu N et al., 2011). Some miRNAs present in exosomes produced by 
cancer cells, can trigger the immune response by binding to Toll-like receptor (Fabbri M, 2012). 
The exosomes can be both mediators and modulators of the immune response and can play a role 
both of inflammatory tumor response that anti-tumor immunity (Figure 12). 
 
 
Figure 12: Role of exosomes in immune response (Schorey JS, 2014) 
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4.5 EXOSOMES AS BIOMARKERS AND ANTI-CANCER DRUG 
 
Several studies have described and demonstrated the role of exosomes as a biomarker for the 
diagnosis of cancer. (Roma-Rodrigues C et al., 2014; Dijkstra S et al., 2014). 
Each tumor is characterized by a particular protein or miRNA profile. Several studies have shown a 
correlation between the protein and miRNA exosomes content with the stadium and the evolution of 
tumor. In metastatic breast cancer cells, have been described a protein, the periostin, which has been 
found and validated in a cohort of patients with breast cancer metastatic lymph nodes (Vardaki I et 
al., 2016). A number of prostate cancer lncRNAs have been identified and 8 specific microRNAs 
have been validated in serum-derived exosomes from ovarian cancer patients whose expression 
levels were similar to those found in cancer cells (Ahadi A et al., 2016; Taylor and Gercel-Taylor, 
2008). Exosomal miRNAs have been studied and identified in several types of cancer suggesting 
that they can play a role of probable prognostic and diagnostic indicators (Wang WT et al., 2014; 
Skog J et al., 2008; Rabinowits G et al., 2009; Lau C et al., 2013). 
Finally, exosomes may be used to carry drugs or nano-molecules against cancer, such as miRNA 
and siRNA (van den Boorn JG et al., 2013; Shtam TA et al., 2013; Zhang HG et al., 2014). 
The use of exosomes as drug-carriers, could bring an advantage in the fight against cancer: 
exosomes derived from autologous tumor cells, may induce less toxicity and immunogenicity to the 
recipient cells, compared to artificial drugs administration; they can fuse directly with the plasma 
membrane, improving drug cellular internalization; finally, their diffusion in the tumor tissues 
would be supported both by their relative stability in biological fluids and by their small size that 
would allow to evade phagocytosis by macrophages (Kosaka N, et al., 2012; Ohno S, et al., 2013; 
Tian Y, et al., 2014; Jang SC, et al., 2013). 
 
4.5 EXOSOMES AND VIRUS 
 
The role of exosomes as viral acid nucleic cargo, has been described initially for the Epstein-Barr 
virus (EBV) and the human immunodeficiency virus (HIV). EBV was the first virus in which were 
found microRNAs (Cai X et al., 2006; Pegtel DM et al., 2010) demonstrated their functionality in 
vitro, transferring exosomes in non-infected cells, through the use of cocultures. In 2000, it was 
shown that the CCR5, HIV coreceptor necessary for viral entry into the cell, can be secreted from 
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CCR5 + cells, in vesicles form, and be transferred to CCR5- cells, demonstrating its capabilities 
(Mack M et al 2000). 
In recent years, the release of viral nucleic acids exosomes content to recipient cells has been 
described in vitro for other viruses, including hepatitis C virus (HCV), hepatitis A virus (HAV) and 
herpesvirus 6 (HHV-6), (Greenhill C, 2013; Feng Z et al., 2013; Ota M et al., 2014). In 2012, Gaiffe 
E et al., described the presence of HPV DNA in cultures of fibroblasts, following exposure with 
apoptotic bodies containing HPV, obtained from HeLa and Caski cell lines (Gaiffe E et al., 2012). 
An alternative infection mechanism was described for HIV. This mechanism, called trans-infection, 
used the uninfected dendritic cell-to capture HIV-1 and mediate viral transfer to T cells (Izquierdo-
Useros N et al., 2012). 
The cargo properties of exosomes, was exploited by viruses to carry and release their viral genome 
into recipient cells and to spread infection. Exosomes enter into receiving cells through binding to 
receptors present on the surface of target cell, or fusing directly with plasma membrane of the cell, 
releasing their contents directly into the cytoplasm (Izquierdo-Useros et al., 2011). This system 
could allow the virus to evade the immune system and promote infection (Gould SJ et al., 2003). 
The mechanisms related to viral transfer, are still unclear, as it is difficult to distinguish exosomes 
from the viral particles. For this reason, some methods have been described which allow to separate 
the virus from exosomes, to understand the virus-exosome complex dynamics (Nolte-'t Hoen E et 
al., 2016; Schwab A et al., 2015). 
The role of exosomes in viral pathogenesis, could be exploited in the future for new vaccines or 
antiviral therapies development (Figure 13). 
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Figure 13: Pathogen-derived molecules identified in exosomes (Fleming A et al., 2014) 
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2. BACKGROUND AND AIM OF THE STUDY 
 
Human papillomavirus (HPV) is one of the most frequently sexually transmitted agent and play a  
causative role in almost all cervical cancers in which HPV DNA is frequently found integrated into 
human genome at fragile sites. HPV DNA has been found also in a series of extra-genital tissues 
such as oro-pharingeal, skin, lung and colon tissues, in which the virus is alleged to exert an 
oncogenic activity. Recently HPV DNA was found to be significantly associated with breast cancer 
in meta-analytic studies (Simões PW et al., 2012; Bae JM, 2016). Despite this finding the role of 
HPV in breast cancer pathogenesis is still a conundrum. Moreover there are no clues about the route 
of HPV dissemination to the mammary gland tissue.  
In this regard, despite the absence of overt viremia, some authors speculate the diffusion of HPV 
from the genital site of infection to other districts, by blood (Hennig EM et al., 1999; 
Widschwendter A et al., 2004). Accordingly, the presence of HPV DNA in blood samples has been 
detected in PBMCs and plasma in patients affected by HPV positive cancers (Bodaghi S et al., 
2005). 
The term microvesicles (MVs) currently includes exosomes, apoptotic bodies and shedding 
microvesicles, which are found in many biological fluids (blood, urine, saliva and milk) and are 
grouped on the basis of biophysical properties (Bobrie A et al., 2013). The process of tumorigenesis 
leads to an increase in exosomes secretion, whose functional properties include modulation of 
angiogenesis, cell invasion, but also the activity as cargo for nucleic acids (Rak J, 2010). Indeed, 
exosomes associates with the transmission of certain pathogens (e.g. HIV) and oncogenes which 
may promote the development of tumors at distant sites as a result of horizontal gene transfer. 
Our preliminary data confirm the presence of HPV DNA in breast cancer tissues and serum. 
Intriguingly, in situ hybridization analysis allowed us to localize the DNA into epithelial and 
stromal compartments of the mammary gland.  
In this study we plan to verify the hypothesis that HPV DNA/RNA takes part to extra-genitals and 
breast cancers pathogenesis. In particular, we aim to shed light on the mechanisms responsible of 
HPV DNA spreading from the primary and canonical site of infection, i.e. genital organs, to the 
others compartments by collecting exosomes through differential ultracentrifugation and CD9-
immunobeads isolation kit. We decided to isolate exosomes from HeLa and Caski cell lines 
supernatant (HPV18 and HPV16 positive, respectively) and from patient serum, urine and liquor 
HPV positive. 
39 
 
In addition, we aim to understand if viral nucleic acid transfer mechanism, can be extended to other 
viruses, such as polyomavirus. SV40 polyomavirus was find in different cancer, including 
medulloblastomas, breast cancer, mesotheliomas (Vilchez RA et al., 2003), but few information are 
available about its role in human tumors and its route of transmission. Our unpublished data 
demonstrated the presence of SV40 DNA positive in bone tumors. We plan to use SV40 positive 
exosomes, isolated by COS7 cell line supernatant (SV40 positive cell line). 
Exosomes obtained will be used to test the hypothesis of viral nucleic acid transfer to recipient 
cells. First, we will analyze their acid nucleic and protein content. Then, we will quantify their 
number by using Nanosight, that could allow us to perform in vitro experiment by using the same 
exosomes number. We will test different recipient cell lines to verify our hypothesis. Exosomes 
exposed cells will be analyzed at different time point of exposure by using Real-time PCR, 
conventional PCR and digital PCR. 
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3. MATERIAL AND METHODS 
 
Cell lines and cultures 
 
MCF7 human breast cancer cells were cultured in RPMI 1640, supplemented with 10% fetal bovine 
serum (Euroclone, Milan, Italy) and 1% penicillin/streptomycin at 37°C in 5% CO2 humidified 
atmosphere. 
Caski and HeLa cervix cell lines, contain Human Papilloma Virus (HPV), HPV16 and HPV18 
respectively. They were cultured in RPMI1640 and DMEM, respectively, supplemented with 10% 
fetal bovine serum (Euroclone, Milan, Italy) and 1% penicillin/streptomycin at 37°C in 5% CO2 
humidified atmosphere. 
COS7 cell line, contains SV40 viral DNA sequences and it was cultiured in DMEM supplemented 
with 10% fetal bovine serum (Euroclone, Milan, Italy) and 1% penicillin/streptomycin at 37°C in 
5% CO2 humidified atmosphere. 
HCT116 and NCM460 (colon cell lines), H2052, SAOS2 and U2OS (mesothelioma and 
osteosarcoma cell lines), COS7 (SV40 trasformed cell line) and A172 (glioblastoma cell line), were 
cultured in DMEM and RPMI1640, supplemented with 10% fetal bovine serum (Euroclone, Milan, 
Italy) and 1% penicillin/streptomycin at 37°C in 5% CO2 humidified atmosphere. 
Normal and Tumoral Human Mammary Fibroblast (NHMF and THMF) were obtained from breast 
patient tissue. After collagenase/hyaluronidase digestion, cells were centrifuged at 500 g for 5 min 
and the pellet containing fibroblasts was suspended in DMEM medium supplemented with 20% 
fetal bovine serum (FBS) (Euroclone, Milan, Italy), penicillin–streptomycin and glutamine (Sigma). 
Hypoxia was obtained by exposing cells to 1% pO2, 5% pCO2, 94% pN2 gas mixtures in an in vivo 
300 Hypoxia Cabinet (Ruskinn Technology, Bridgend, UK). 
 
Mammospheres generation from normal tumor human breast tissues 
 
Tumor samples (ductal breast carcinoma) were separated from the surrounding normal tissue, under 
sterile conditions, and were diagnosed as normal or neoplastic, following standard diagnostic 
procedures.
 
Normal and tumor tissues were processed to generate MS. Cells were filtered through a 
40 µm nylon mesh (Becton Dickinson, Franklin Lakes, NJ) and were suspended in 1.5 cm2 low 
attachment wells (Becton Dickinson) with 1 ml of complete Mammary Epithelial Growth Medium 
(MEGM) supplemented with B27, Epidermal and Fibroblast Growth Factors, Insulin and 
Hydrocortisone (Lonza, Basel, Switzerland). Primary MS started forming after 4–6 days and 
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processed for secondary MS. The procedure was approved by the local ethical committee and by the 
patients written informed consent. 
 
Specimens 
 
This study was approved by the local ethics committe (number 145/2015/U/Sper; number 
006/2012/U/Tess). All patients gave written informed consent in accordance with the Declaration of 
Helsinki. 
 
Exosome isolation 
 
Differential Ultracentrifugation 
Exosomes were isolated from normoxic and hypoxic cells-conditioned medium, and from serum-
derived patient, as recently reported (King et al., 2012). HeLa, Caski and COS7 cells were cultured 
in medium serum free, for 48 h. Briefly, the medium or serum patient, were first centrifuged at 500g 
for 10 min to spin down intact cells and next at 20.000g for 20 min to pellet cell debris. Finally, the 
supernatant or serum were ultracentrifugated at 100.000g for 120 min to obtain the exosome pellet, 
which was washed in PBS and centrifuged again at 100.000g for 120 min. Exosome pellet was re-
suspended in 50 µl of PBS. Exosomes were DNASE 1 digested (DNase I RNase-free 1 U/µL, 
Thermo Fisher, EN0521) prior to nucleic acid extraction. 
CD9 immunobeads isolation kit 
 
Exosome biologic fluids, including serum, urine and liquor were isolated by CD9 immunobeads 
isolation kit (Hansa-Biomed) according to the manufacturer’s protocol. Briefly, biological fluids 
samples, were first subjected to different centrifugation to spin down cell debris. 10 µl of 
immunobeads were added to samples, and were incabate 4°C overnight in rotator. The day after, 
samples were subjected to several centrifugated of 5000 rpm for 10 min, to collect the CD9 
negative fraction. Immunobeads were resuspended and centrifugated twice 5000 rpm for 10 min, 
with 50 µl of exosomes eluition buffer to collect two CD9 positive fractions. 
Exosomes can be used to make in vitro transfers or can be analyzed at molecular level: they are 
resuspended with RIPA buffer for protein extraction, TRIzol® (Life Technologies, Milano, Italy) 
for total RNA extraction, or Lysis Buffer for DNA extraction. 
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Exosome transfer 
 
Exosomes obtained by differential ultracentrifugation or CD9-immunobeads isolation kit, were 
analyzed by using the NS500 nanoparticle characterization system (Nanosight Malvern 
Instruments) thanks to collaboration with IRST (Meldola). This instrument allows to misure 
exosomes distribution, number/ml and mean size plotted as a diagram file. Exosomes quantification 
allow us to performed in vitro experiments with the same vesicles number. We exposed cells to the 
same vesicles number and we analyzed acid nucleic transfer at different timepoint. 
 
RNA extraction with Trizol 
 
Cells and exosomes RNA extraction were performed by Trizol protocol (Life Technologies, 
Milano, Italy). Pellet cell or exosomes were resuspended in 400 μl of Trizol and mixed. 160 μl of 
chloroform were added, and incubated for 5’ at RT. After centrifugation at 12,000xg for 15’ at 4°C, 
the upper phase was transferred to a new fresh tube. 200 μl of isopropanol and 2 μl of glycogen 
were added to the sample and mixed by inversion several times, and incubated for 10’ at 4°C. The 
samples were then centrifuged at 12,000xg for 15’ at 4°C. The supernatant was discarded and the 
pellet washed in 500 μl of 75% EtOH. The RNA was pelleted with a centrifugation at 12,000xg for 
10’ at 4°C, air dried and resuspended in 12 μl of DEPC H2O. RNA was stored at -80°C. 
The RNA concentration was measured by Thermo Scientific NanoDrop™ 1000 Spectrophotometer. 
 
DNA extraction 
 
Cells, exosomes and formalin-fixed, paraffin-embedded (FFPE) tissues samples DNA extraction 
were performed by Nucleo Spin Tissue or Nucleo Spin FFPE Tissue (Machery-Nagel) respectively. 
Pellet cells, exosomes and FFPEs samples were resuspended in lysis buffer and proteinase k and 
were incubated for 10’ to 70°C (pellet cells and exosomes) or overnight to 70°C (FFPEs samples). 
Samples were transferred on the appropriate columns and centrifugated at 11000g for 1’. The 
supernatants were discarded and samples were washed and centrifugated at 11000g for 1’ again. 
This step was repeated three times. DNA was eluted with 30-100 μl of eluition buffer. Dna 
concentration was measured by Thermo Scientific NanoDrop™ 1000 Spectrophotometer and stored 
at -30°C. 
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Real-time PCR on DNA and cDNA 
 
An amount of 0.1-1 µg of total RNA was retro-transcribed by using the Master RT plus PCR system 
kit (LifeTechnologies). The reaction is composed by: 
  
STEP 1: 
REAGENT VOLUME (µL) 
Oligo dt or Random Primers 1 
dNTPs 1 
RNA 0.1 – 1 µg 
H20 Up to 12 µL 
 VOLUME FINAL: 12 µL 
 
 
STEP 2: 
REAGENT VOLUME (µL) 
Buffer 5x 4 
DTT 2 
MMLV 1 
Rnase Out 1 
 VOLUME FINAL: 8 µL 
 
The program machine is: 
STEP 1 TEMPERATURE DURATION CYCLES 
 65°C 5 min 1 
 4°C for ever  
 
STEP 2 TEMPERATURE DURATION CYCLES 
 37°C 50 min 1 
 72°c 15 min 1 
 4°C for ever  
 
cDNA and DNA were amplified by Syber Green (SYBR® Select Master Mix for CFX, Life 
Technologies) or Taqman (Taqman Universal Master Mix, Life Technologies) approaches, by using 
Mx3000P Stratagene instrument (Thermo Fisher) following the manufacturer's instruction. The data 
was analyzed by using the 2
−ΔΔCT
 method. The beta-glucuronidase and Beta-Actin, were used as 
endogenous controls for cDNA or DNA analysis, respectively. Each sample was analyzed in 
replicate. All primers used in Real-time PCR are listed in table. 
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REAGENT VOLUME (µL) 
Taqman Universal Master Mix (2x) / SYBR® 
Select Master Mix for CFX (2x) 
5 
Probe Taqman/ Primer Fw and Primer Rev Variable 
Sample + H2O Variable 
 VOLUME FINAL: 10 µL 
 
Real-time TAQMAN program machine: 
STEP TEMPERATURE DURATION CYCLES 
Udg activation 50°C 2 min 1 
Amplitaq DNA polymerase activation 95°c 2 min 1 
Denature 95°C 15 sec  
Anneal/Extend 60°C 1 min 45 
 
Real-time Syber Green program machine: 
Primer TM > 60°C 
STEP TEMPERATURE DURATION CYCLES 
Udg activation 50°C 2 min 1 
Amplitaq DNA polymerase activation 95°c 2 min 1 
Denature 95°C 15 sec  
Anneal/Extend 60°C 1 min 45 
 
Primer TM < 60°C 
STEP TEMPERATURE DURATION CYCLES 
Udg activation 50°C 2 min hold 
Amplitaq DNA polymerase activation 95°c 2 min hold 
Denature 95°C 15 sec  
Anneal 55-60°C 15 sec 45 
Extend 72°C 1 min  
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Pcr standard and nested 
 
DNA and cDna were amplified by a PCR standard reaction using a T100 Thermal cycler Bio-Rad 
or GeneAmp® PCR System 9700 (Applied Byosistem) machines. Each amplification reaction was 
performed by GoTaq®Flexi DNA Polymerase kit (Promega). Pcr products were detected on 1.8% 
agarose gel by using ChemiDoc™ XRS+ System (Bio-Rad). Nested pcr was performed to increase 
the sensitivity and/or specificity of PCR. The primers used in the first round of amplification are 
either both replaced for the second and subsequent cycles of amplification. In alternative, the 
primers used for the second amplification, are internal to the original primers used to generate that 
amplicon. All primers are listed in table. 
 
PCR MIX REACTION: 
REAGENT VOLUME (µL) 
5X Colorless GoTaq® master mix 5 5 
25 mM MgCl2 2 2 
10 μM dNTPs mix 1 
10 μM Primers mix 0.5 
5 U/μl GoTaq®Hot Start Polymerase 0.125 
Sample Variable 
H20 Variable 
 FINAL VOLUME = 25 µL 
 
PCR Amplification Program: 
STEP TEMPERATURE DURATION CYCLES 
GoTaq®Hot Start Polymerase 
Activation 
95°C 2 min 1 
Denaturation 95°c 2 min  
Annealing 60°C 30 sec 35-45 
Extension 72°C 1 min  
Final extension 72°C 7 min 1 
 4°C Hold  
 
Western Blot 
 
Total proteins were extracted with RIPA Buffer (25 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1% NP-
40, SDS 0.1%, Na-Deoxycholate 0.5%) added with Protease Inhibitor Cocktail (Roche, Basel, 
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Switzerland). The pellet was re-suspended in RIPA buffer and incubated on ice for 20 min; next the 
supernatant was recovered by centrifugation at 13.000g for 15 min. Proteins were analyzed by 
Western blot using the following antibodies: anti-CD81 (clone MA5-13548, ThermoFisher); anti-
CD63 (MEM-259, Thermo Fisher), anti-CD9 (clone MA1-80307; Invitrogen ), anti-Alix (clone 
3A9, MCA2493, Biorad). 
 
Chromogenic in Situ Hybridization (CISH) 
 
Chromogenic in Situ Hybridization (CISH) was used to detect HPV DNA in tissues. CISH was 
performed by using the ZytoFast®Plus CISH Implementation Kit HRP-AEC (ZytoVision) using 
digoxigenin-labeled probes according to manufacturer’s protocol. The presence of HPV DNA in 
tissues was analyzed by using a probe able to recognize both the HPV16/18 DNA (ZytoFast®HPV 
type 16/18 Probe Digoxigeninlabeled). A probe specific for the ALU sequences, provided by the 
kit, was used as a positive control (ZytoFast®DNA (+) Control Probe).  
 
Digital Pcr 
 
Some DNA samples, were analyzed by Digital PCR (QuantStudio
®
 3D Digital PCR System, Life 
Technologies), to determine absolute quantification of viral copy number. To detect target sequence 
were used Taqman assay or primers with specific UPL probe (Roche). Standards or endogenous 
controls were not used because only target sequences were detected. The amplification reaction is 
composed by a mixture of sample, master mix and probes. They were coated on chip, through a 
nanofluidic and automatic system. Chip containing sample, was covered by oil, closed and 
amplified by using QuantStudio® 3D Digital PCR System. Chip is read and subsequently 
analyzed by using its software. To account for wells that may have received more than one 
molecule of the target sequence, a correction factor is applied using the Poisson model. All primers 
used for dPCR assay are in table. 
 
Statistical analysis 
Statistical analysis was performed by SPSS software v10 (SPSS, Chicago, IL). Quantitative 
variables were assessed by student’s t test. P-values were adjusted for multiple comparisons when 
n>2 samples were compared. 
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Table 1. Housekeeping primers 
GENE SEQUENCE POSITIO
N 
LENGH
T 
ASSAY TARGE
T 
ACTB CCACACTGTGCCCATCTACG F 1456 98 bp Real-time 
PCR 
DNA 
AGGATCTTCATGAGGTAGTCAGTC
AG 
 
R 1358 
ACTB  
Taqman probe (Life Technologies) 
  Real-time 
PCR/Digita
l PCR 
DNA 
GUS Taqman probe (Life Technologies)   Real-time 
PCR 
RNA 
 
Tabella 2. HPV18 primers 
GENE SEQUENCE POSITION LENGHT ASSAY TARGET 
E7 HPV18 GAAAGCTCAGCAGACGACCT F 818 63 bp Real-time 
PCR 
DNA 
CACAAAGGACAGGGTGTTCA R 880 
 
Tabella 3. HPV31 primers 
GENE SEQUENCE POSITION LENGHT ASSAY TARGET 
E6/E7 
HPV31 
GTGGACAGGACGTTGCATAG 
 
F 818 185 bp Real-time 
PCR 
DNA 
GCTGGACTGTCTATGACATC 
 
R 880 
 
Tabella 4. HPV16 primers 
GENE SEQUENCE POSITION LENGHT ASSAY TARGET 
E6 
HPV16 
CAACAGTTACTGCGACGTGAG F 206 349 bp PCR DNA 
GCTGGGTTTCTCTACGTGTTC R 554 
E7 
HPV16 
CAACTGATCTCTACTGTTATGAGC
AA 
F 617 73 bp Real-time 
PCR/ Digital 
PCR 
DNA 
CCAGCTGGACCATCTATTTCA R 689 
E1 
HPV16 
Taqman probe (Life Technologies)   Real-time 
PCR/Digital 
PCR 
DNA 
 
Tabella 5. SV40 primers 
GENE SEQUENCE POSITION LENGHT ASSAY TARGET 
Large T 
SV40 
TCAGCAGAGCCTGTAGAAC F 3670 107 bp PCR DNA 
AAGCGGGTTGATAGCCTAC 
 
R 3776 
Large T 
SV40 
GCCTCATCATCACTAGATGC F 4471 468 bp PCR DNA 
AGGCTTCTGGGATGCAACTG R 4939 
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4. RESULTS 
 
HPV AND BREAST CANCER 
 
On the basis of meta-analysis studies (Bae JM, 2016) about the presence of HPV in breast cancer 
patients, we hypothesized that the virus could occur in these tissues. 273 FFPE breast cancer tissues 
were analyzed by MALDI-TOF mass-spectrometry (Cricca et al., 2015). In particular, the samples 
were subjected to 16 mucosal HPVs genotypes analysis, that included high and medium risk 
genotypes. We found 30% of HPV DNA positive samples, including 20% of HPV16 single 
infection, 7% of other genotypes (18,31,33,35,53,58,68) and 3% of multiple infections with HPV16 
(Figure 1). 
 
  
Figure 1. Maldi-TOF mass spectrometry (MS)-based method analysis for 16 mucosal high risk HPV genotypes. 
Analysis shows 30% of HPV positive samples, including 20% of HPV16 genotype single infection prevalence. 
 
 
 
 
 
 
 
 
20% : HPV16 SINGLE INFECTION 
7% : OTHER GENOTYPES 
(18,31,33,35,53,58,68) 
3% : MULTIPLE INFECTION WITH 
HPV16 
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The presence of HPV DNA was also observed and confirmed with in situ hybridization assay (ISH) 
(Figure 2). 
 
 
Figure 2: ISH assay shows HPV16 positive tissue. 
 
Two HPV 16 DNA positive as well as 7 HPV DNA negative breast cancer tissues, belonged to a 
case set of patients whose mammospheres (MS) and human mammary fibroblasts (HMF) had been 
previously isolated (Papi et al., 2014).  We were able to find HPV16 DNA in both MS and HMF 
from the HPV DNA positive tissues but not from HPV DNA negative ones. One out of the two 
HMF HPV16 DNA+ was long-term cultured up to passage twelve. The HMF HPV16+ DNA was 
analyzed at 3, 6 and 12 cell passages for the presence of HPV16 DNA, through the Real-Time PCR 
(Figure 3A and 3B). 
A 
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B 
 
 
Figure 3. A: PCR analysis of HPV16 DNA in 9 MS and HMF breast cancer specimens; 2 out of 9 HMF and MS result 
HPV DNA positive for 16 genotype. B: Real-time PCR analysis of HPV16 DNA in HMF HPV16+ at 3, 6 and 12 
passages. 
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HPV DNA+ serum-derived exosomes from breast cancer patients  
 
We have isolated exosomes from 59 serum specimens from breast cancer patients by differential 
ultracentrifugation method and we searched for the presence of HPV DNA by a Real-Time PCR 
assay specific for the E7 gene of HPV 16, 18 and 31. We identified 5 HPV DNA+ samples, 
including 2 HPV16, 1 HPV16/HPV31, 1 HPV18, and 1 HPV31 (Figure 4).  
 
 
 
Figura 4. Real-Time PCR analysis of HPV16, HPV18 and HPV31 DNAs in HPV DNA+ serum-derived exosomes.  
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Subsequently, we analyzed the presence of exosomes markers, i.e CD9, CD63 and CD81 (Figure 
5). 
 
Figure 5. Western Blot analysis of exosomes markers, including CD9, CD63 and CD81. 
 
Viral nucleic acids transfer from HPV DNA + serum-derived exosomes to recipient cells 
 
HPV DNA+ serum-derived exosomes, were used to test in vitro the viral nucleic acid transfer to 
recipient cells. We exposed MCF7 and HMF, to the HPV DNA+ serum-derived exosomes up to 5 
days. We found two HMF HPV16+ samples (Figure 6).  
 
 
Figure 6. HPV16 DNA analysis of HMF exposed to HPV DNA+ serum-derived exosomes by PCR. Two samples result 
positive for HPV16 genotype. 
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Viral nucleic acids transfer from HPV DNA positive cell lines exosomes to recipient cells 
 
We performed our in vitro experiments using the exosomes derived from the cervical HPV DNA 
positive cell line, Caski (HPV16 positive). We collected 80 ml of serum deprived supernatant and 
we isolated exosomes by differential ultracentrifugation. The exosomes were purified by filtering at 
0.1 and 0.22 µm particle size as well as in absence of any filtration. We evaluated the amount of 
viral nucleic acids in the exosomes by Real-time PCR (Figure 7).  
 
 
           
 
 
 
Figure 7. DNA and RNA HPV16 analysis by Real-time PCR of Caski-derived exosomes isolated by differential 
ultracentrifugation. We used 0.1 µm, 0.2 µm filters and no filters to evaluate HPV acid nucleic content. The analysis 
shows a significant viral nucleic acid content decrease by using filter. 
 
 
 
 
 
 
Caski-derived exosomes 
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We analyzed protein content of 0.22 µm or not filter Caski-derived exosomes. We searched for 
three markers exosomial proteins, including Alix, CD63 and CD9 (Figure 8) 
 
 
 
Figure 8. Western Blot analysis of 0.22 µm and no filter Caski-derived exosomes. 
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Caski-derived exosomes were analyzed by Digital PCR to evaluate the number of HPV16 E1 and 
E7 gene copies in normoxia and hypoxia condition (1% pO2). We also performed a DNAse 1 
digestion prior to nucleic acid extraction to verify the effective presence of HPV DNA inside the 
exosomes. We showed the presence of HPV DNA also after the DNAse I treatment (Figure 9). 
 
 
 
 
 
Figure 9: Digital PCR analysis of Caski-derived exosomes. We evaluated both Caski and Caski-derived exosomes 
DNA viral copies. We isolated Caski-derived exosomes after 48h of normoxic or hypoxic condition. The analysis 
shows that HPV DNA is still present after DNASE 1 digestion. 
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We analyzed Caski derived-exosomes by using the NS500 nanoparticle characterization system 
(NanoSight, Malvern Instruments) in collaboration with Istituto Scientifico Romagnolo per lo 
Studio e la Cura dei Tumori (IRST, Meldola). This instrument calculates number/ml and mean size 
of exosomes. It allowed us to use the same number of exosomes in our experiments. Caski derived-
exosomes were used to carry out the viral nucleic acid transfer on normal and tumor HMF. We 
observed an increase of DNA and RNA up to day 7 and a decrease at day 10 of exposure. (Figure 
10 A and B) 
 
A 
 
 
 
 
SAMPLE MEAN 
(nm) 
SD 
(nm) 
PARTICLE/ML 
ESO CASKI 
NOR 
140.2 73.3 1.98x10^10 
ESO CASKI 
HYP 
161.6 60.8 2.02x10^10 
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B 
 
Figura 10. A: Nanosight plot representation of Caski-derived exosomes. B: HMF exposed to Caski-derived exosomes 
was analyzed by PCR assay. This analysis shows that both DNA and RNA are present after 7 day of exposure in 
exposed to Caski-derived exosomes. 
 
The presence of HPV DNA in HMF exposed to Caski derived-exosomes was evaluated in 4 sets of 
experiments at day 7 of exposure. Results obtained confirm the presence of HPV16 DNA in normal 
and tumor fibroblasts (NHMF; THMF) exposed to Caski derived-exosomes, albeit with a little 
variability of HPV DNA expression (Figure 11). 
 
 
Figure 11: Real-time PCR analysis of HPV16 DNA in NHMF and THMF exposed to Caski derived-exosomes in 4 
replicates samples. HPV16 DNA presence is similar among the different replicates. Only THMF R3 and R4 present a 
little variability of HPV DNA expression. 
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We analyzed gene expression of some markers about proliferation, inflammation and tumor 
aggressiveness in NHMF and THMF exposed to Caski derived-exosomes. We observed C-MYC 
and CYC-D1 expressions increased, that regulate growth and cell proliferation. We also detected an 
enhancement of Interleukin6 (IL6), especially in exposed THMF. Finally, we observed an increase 
of CD44 expression in HMF exposed to Caski derived-exosomes, that indicating the activation and 
the enhanced metabolic activity of fibroblasts (Figure 12).  
The increased expression of these genes leads to the assumption that the presence of exosomes in 
the recipient cell, lead to an aggressive phenotype. 
 
 
Figure 12: C-MYC, CYC-D1, IL6 and CD44 expressions were analyzed in NHMF and THMF exposed to Caski-
derived exosomes by Real-Time PCR. Obtained data show an increased expression of Caski-derived exosomes in 
NHMF/THMF- exposed to Caski-derived exosomes. 
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We analyzed 2 out of 4 THMF exposed to Caski derived-exosomes (R3 and R4), characterized by a 
different content of HPV DNA, to understand whether the increased expression of the genes 
previously analyzed, depend on the viral nucleic acids presence. We analyzed CD44, IL6; C-MYC 
and CYC-D1 expressions and we observed an increased of these genes in fibroblast with a higher 
content of HPV DNA. These analysis indicate that the presence of viral nucleic acids can influence 
cell phenotype (Figure 13). 
 
Figure 13: R3 and R4 THMF samples present a different HPV DNA level (Figure 10). We analyzed CD44, IL6, C-
MYC, CYC-D1 expression in these samples by Real-time PCR. R4 THMF sample, that presents an higher HPV DNA 
content, shows an increasead of CD44, IL6, C-MYC and CYC-D1 gene expression, compared to R3 THMF. 
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We also analyzed DNA from tissue of breast cancer xenograft injected with 10^6 HPV positive 
exosomes, obtained from a collaboration with a Memorial Sloan Kettering Cancer Center research 
team. Breast cancer xenograft developed 8 tumors and one of these was found DNA HPV16+ by 
PCR. Breast cancer xenograft HPV16 positive tissue was analyzed by ISH assay, confirming 
positivity for this HPV16 genotype (Figure 14 A and B). 
 
A 
 
B 
 
Figure 14: A: Conventional and Nested PCR confirmed HPV16+ DNA in one of breast cancer xenograft tumor tissue 
(tumor 5); B: ISH assay of tumor 5 confirmed HPV16 positive genotype. 
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CASE REPORT 1: HPV AND ECTOPIC RECTAL 
SPINOCELLULAR CANCER 
 
We analyzed the presence of viral nucleic acids in the serum-derived exosomes of a patient with an 
HPV16 positive ectopic rectal spinocellular cancer. We were able to recover the patient's serum, 
from which we isolated exosomes by CD9-immunobeads isolation kit. We observed the presence of 
HPV16+ DNA exosomes (Figure 15 A and B). 
 
A 
      
B  
 
Figura 15. A: ISH assay shows a HPV16 DNA positive mass. We analyzed and sequenced DNA from HPV16+ mass 
tissue and we confirmed HPV16 positive. B: DNA of serum-derived exosomes is analyzed by PCR resulting HPV16 
genotype positive. 
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Subsequently, we used HPV16+ serum-derived exosomes to perform in vitro studies. In particular, 
we exposed two HPV DNA negative colon cell lines, HCT116 and NCM460, to the patient 
HPV16+ serum-derived exosomes. We collected the exposed cells at 3, 6 and 20 hours and we 
found the presence of HPV16 DNA up to 6 hours in both cell lines and up to 20 hours in NCM 
cells. By Real time PCR we observed a low amount of E1 HPV16 also at 20 hours in HCT and at 3 
hours in NCM. We were able to estimate both E1 and E7 HPV16 genes copies in 
HCT116/NCM460 exposed to HPV16+ serum-derived exosomes by Digital PCR. This analysis 
shows a low viral content transfer to recipient cell (Figure 16 A, B and C). 
 
A 
 
B  
        
 
 
 
 
 
 
1: HCT116 exposed to HPV16+ serum-derived exosomes 3h 
2: HCT116 exposed to HPV16+ serum-derived exosomes 6h 
3: HCT116 exposed to HPV16+ serum-derived exosomes 20h 
4: NCM460 exposed to HPV16+ serum-derived exosomes 3h 
5: NCM460 exposed to HPV16+ serum-derived exosomes 6h 
6: NCM460 exposed to HPV16+ serum-derived exosomes 20h 
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C 
           
Figure 16. A: We analyzed HPV16 DNA in HCT116 and NCM460 exposed to HPV+ serum-derived exosomes at 
different time point (3h, 6h and 20h) by PCR. We found HPV16 DNA in both cell lines. B: We confirmed PCR data, by 
using Real-time PCR. We also found E1 HPV16 in HCT116 exposed to 20h and NCM exposed to 3h. C: We analyzed 
E1 and E7 HPV16 DNA viral copies by using Digital PCR. The data obtained show a low HPV DNA copies in both 
cell lines exposed to HPV+serum-derived exosomes. 
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CASE REPORT 2: HPV DNA+ ORAL CANCER AND INFLAMMATORY 
CNS NEUROPATHY OF UNDERMINED ORIGIN 
 
We analyzed the liquor, serum and urine-derived exosomes of a patient with an HPV positive oral 
cancer who developed an inflammatory CNS neuropathy of undetermined origin. We hypothesized 
that HPV could be involved in this disorder. We isolated exosomes by CD9-immunobeads isolation 
kit. Both the CD9+ and the CD9- fractions were analyzed for the presence of HPV DNA and we 
determined the presence of viral nucleic acids in the CD9+ fractions from serum and liquor 
specimens. We also determined a low amount of HPV DNA in the CD9– fraction from urine. The 
positive samples were purified and sequenced and we found HPV16 genotype (Figure 17 A and B).  
 
A 
 
B 
 
Figure 17. A: HPV degenerate primers (MY09-11) were used to analyzed liquor, serum and urine-derived exosomes by 
using PCR. B: HPV DNA positive sample were sequenced and we found 3 HPV16 positive genotype. 
We decided to expose a glial cell line, A172, to Caski derived-exosomes and we analyzed the 
presence of HPV16 DNA at two different timepoints, 6h and 24h by using PCR, Real-Time PCR 
and Digital PCR. We observed a low amount of HPV DNA persistence up to 24 hours both by 
using normoxic and hypoxic exosomes (Figure 18 A, B and C).  
1: Blank 
2: Serum-derived exosomes CD9+ 
3: Serum-derived exosomes CD9- 
4: Serum-derived exosomes CD9+ 
5: Serum-derived exosomes CD9- 
6: Urine-derived exosomes CD9+ 
7: Urine-derived exosomes CD9- 
8: Liquor-derived exosomes CD9+ 
9: Liquor-derived exosomes CD9- 
10: K+ 
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A 
 
 
 
 
 
 
B 
 
 
 
 
1: K- 
2: A172 exposed to Caski-derived exosomes Nor 6h 
3: A172 exposed to Caski-derived exosomes Hyp 6h 
4: A172 exposed to Caski-derived exosomes Nor 24h 
5: A172 exposed to Caski-derived exosomes Hyp 24h 
6: Caski-derived exosomes Normoxia 
7: Caski-derived exosomes Hypoxia 
8: Caski 
9: Blank 
1: A172 EXPOSED TO CASKI-DERIVED EXOSOMES NOR 6h 
2: A172 EXPOSED TO CASKI-DERIVED EXOSOMES HYP 6h 
3: A172 EXPOSED TO CASKI-DERIVED EXOSOMES NOR 24h 
4: A172 EXPOSED TO CASKI-DERIVED EXOSOMES HYP 24h 
1: A172 EXPOSED TO CASKI-DERIVED EXOSOMES NOR 6h 
2: A172 EXPOSED TO CASKI-DERIVED EXOSOMES HYP 6h 
3: A172 EXPOSED TO CASKI-DERIVED EXOSOMES HYP 24h 
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Figure 18. A: We observed both E1 and E7 HPV16 DNA presence in A172 exposed to Caski-derived exosomes, 
analyzed by Real-time PCR. B: Conventional PCR confirmed HPV16 DNA presence in A172 exposed to Caski-derived 
exosomes up to 20h. C: We also evaluated E1 and E7 HPV16 DNA viral copies in A172 exposed to Caski-derived 
exosomes and we found both E1 and E7 HPV16 copies in recipient cells by using Digital PCR. 
 
 
POLYOMAVIRUS 
 
We analyzed SV40 DNA in 70 samples of bone tumors and we found 7 positive samples including 
4 osteosarcoma (OS), 2 condrosarcoma (CS), and one giant cell tumor (Figure 19). 
 
Figure 19: SV40 positive samples in bone tumors. 
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We isolated COS7-derived exosomes (SV40 positive cell lines), by differential ultracentrifugation. 
We exposed three osteosarcoma cell lines, U2OS, H2056 and SAOS2 to SV40 DNA positive 
exosomes.  We observed the presence of SV40 DNA in SAOS and H2056 cells up to 7 days and in 
U2OS in normoxic and hypoxic condition (Figure 20). 
 
 
 
 
Figure 20. SV40 DNA was detected in SAOS2, H2056 and U2OS exposed to COS7-derived exosomes at different time 
point and different oxygene percentage condition (normoxic and hypoxic) by PCR assay. We used two different primers 
set that amplify Large T SV40 regions. 
 
 
 
 
 
 
 
 
 
 
 
 SAOS2                 H2052            U20S 
68 
 
We also observed an overexpression of IFI16, a gene of the interferon system, in COS7-derived 
exosomes exposed cells. This gene is involved in the natural immune response to the viral nucleic 
acids entry (Figure 21). 
 
 
Figure 21. IFI16 expression was found in SAOS2 exposed to COS7-derived exosomes at 4 and 7 day by Real-Time 
PCR. 
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DISCUSSION 
 
Breast cancer is a very frequent pathology, mainly in the female population, representing 23% of 
diagnosed pathologies and 14% of mortality (Jemal A et al., 2011 and Italian Tumor Registry). It is 
divided according to its molecular and histological characteristics (Lopez LO et al., 2008; Sorlie et 
al., 2004), which give a greater or lesser aggressiveness to the tumor. Although breast cancer is well 
characterized, there are some aspects that are still being studied today. In 1992, the first work that 
described the presence of Human Papillomavirus (HPV) in breast tissue and lymph nodes appeared 
in the literature, with a prevalence of 29.4% (Di Leonardo A, 1992). Subsequently, meta-analysis 
studies have illustrated the relationship between HPV and breast cancer (Simoes PW et al., 2012; 
Bae JM, 2016). In line with the literature, we have searched HPV, in a retrospective case set of 273 
breast cancer tissue samples. By a MALDI TOF mass spectrometry assay we found 30% of positive 
HPV DNA positive samples. The HPV DNA positive tissues, were subjected to further 
investigation and we were able to observe the presence of HPV by ISH assay. We also isolated 
HPV16 positive mammospheres (MS) and mammary fibroblasts (HMF) from two HPV DNA 
positive tissues. We were able to in vitro expand HMF for several passages, demonstrating the 
persistence of HPV 16 DNA. These data bring to light that the stroma is a district in which not only 
we would never expect to find out HPV DNA but where HPV is able to “survive” for long time.  
HPV is a double-stranded circular DNA virus of about 8000 bp, which represents one of the most 
frequent sexually transmitted infection (Doorbar J et al., 2012). HPV requires a multilayered 
mucosal and epithelial cells to replicate, i.e. genital, oral and cutaneous districts, and its complete 
replicative cycle is strictly dependent by the state of cell differentiation. Owing to the lack of 
viremia, HPV DNA presence in the mammary gland is still a conundrum. In this regard recent 
literature reports the presence of circulating HPV DNA in women with cervical lesions (Lawson JC 
et al., 2016).   
Exosomes are small extracellular vesicles of 40-140 nm, released from different types of tissues, 
cells and biological fluids (Raposo G et al., 2014) and are formed during the composition of 
multivesicular bodies. Exosomes contain nucleic acids, proteins, non-coding RNAs (Yanez-MO M 
et al., 2015), and in recent years it has been demonstrated the presence of a viral nucleic acids 
content (Pegtel DM et al., 2010; Mack M et al., 2000; Esther Nolte-‘t Hoen E et al., 2016). We 
hypothesized that the presence of HPV DNA in the breast tissue could be in relation to the 
microvesicles and exosomes contents. 
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On the basis of these observations, we isolated by differential ultracentrifugation exosomes from 59 
serum samples of patients suffering from breast cancer, obtaining 5 HPV DNA positive samples, 
including, HPV16/31, HPV18, HPV31 and two HPV16. These HPV DNA positive exosomes were 
used to test in vitro the efficacy of HPV DNA transfer in MCF7 and the HFM recipient cells. We 
observed that the viral DNA was transferred in HFM but not in MCF7 cells. Based on this 
observation we isolated exosomes by differential ultracentrifugation from the supernatant of HPV 
DNA positive cell lines (Caski), we evaluated HPV DNA viral copies by using Digital PCR and 
then we performed in vitro studies to verify the capability of these exosomes to transfer HPV DNA 
to HFM. We also analyzed exosomes number by using Nanosight and we exposed cells to the same 
number of exosomes. We analyzed the exposed cells at different time points, noting an increase of 
HPV DNA up to 7 days of exposure, then HPV DNA tends to decrease. This could suggest that 
viral nucleic acids cargoed by exosomes, are able to enter into the cell, but obviously need of other 
conditions to persist in the receiving cell. The delivery of HPV DNA via apoptotic bodies to 
recipient cells was previously reported by Gaiffe et al. (2012). 
Several studies report that exosomes, are responsible for increased cell invasion and proliferation, 
influencing the phenotype and cellular functions (Yanez-Mo M et al., 2015). Based on these 
observations, we analyzed some markers responsible for these cellular changes in HFM exposed to 
HPV positive exosomes. We observed an increase of C-MYC, CYC-D1, IL6 and CD44, especially 
in samples with a higher HPV DNA content. These data seem to indicate that the entry of HPV+ 
exosomes in the fibroblast, create a cell failure, bringing the system to become more aggressive and 
more tumorigenic.  
We also found 1/8 HPV DNA positive tumor tissue of breast cancer xenograft injected with HPV 
positive exosomes, confirmed by ISH assay. These data confirm the role of exosomes as carriers of 
viral nucleic acids, and the HPV oncogenic activity in extra-genital tissue. 
The presence of HPV has been found not only in mammary tumors, but also in other districts, such 
as lung cancer (Colombara DV et al., 2015), head and neck cancer (Zur Hausen H et al., 2009), 
colorectal cancer (Yavuzer D et al 2009) and glioblastoma (Vidone M et al., 2014), where the tumor 
microenvironment, could act as a trigger for a viral infection in an already compromised system. 
In this regard, we were able to isolate HPV16 positive serum-derived exosomes by a CD9 
immunobeads isolation kit from a patient with an ectopic rectal spinocellular cancer, whose mass 
was positive for HPV16. We then tried to reproduce what happened in vivo, by exposing the 
HCT116 and NCM460, two colon cell lines, to HPV16+ serum-derived exosomes. The transfer, 
showed us, that HPV16 positive serum-derived exosomes release their viral content in these cells. 
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It has been described that the frequent change of partners and certain sexual habits, may be 
responsible for the presence of HPV DNA positive lesions of the oral cavity (Rautava J et al., 
2012). At this regard we isolate exosomes from serum, urine and liquor specimens (by CD9 
immunobeads isolation kit) from a patient who suffered from an HPV DNA positive oral cancer 
who has presented a CNS neuropathy of undetermined origin with imaging features of 
inflammatory disease after the removal of the oral cancer. We analyzed the exosomes for HPV 
DNA and we were able to find HPV16 DNA in the serum and in the liquor. We tried to transfer 
HPV16 positive Caski-derived exosomes to glia cells (A172) to verify the capability to transfer 
viral DNA and we noticed a low efficiency of HPV DNA delivery. The obtained data allow us to 
speculate that the nervous cells are less susceptible to the viral entry. 
In last period of my theses I focused my research on SV40 polyomavirus. This polyomavirus is 
widely studied in the literature and have been associated with different kinds of pathologies 
(Diamandopoulos GT et al., 1972; Lednický JA et al.,1995; Huang H et al., 1999; Carbone et al., 
1996). In particular, SV40 is a virus that was isolated in humans for the first time in the ‘60s, after 
the administration of a contaminated polio vaccine. SV40 has been associated with a variety of 
cancers in animal and also in humans (Vilchez RA et al., 2003). The literature reports the presence 
of SV40 in medulloblastomas, breast cancer, mesotheliomas but few information are available 
about its role in human tumors and its route of transmission. Our unpublished data demonstrated the 
presence of 7 out of 70 SV40 DNA positive bone tumors, including 2 condrosarcoma (CS), 4 
osteosarcoma and one giant cell tumor. We isolated by differential ultracentrifugation exosomes 
from an SV40 positive cell line (COS7) and we performed in vitro experiments to verify their 
capability to transfer SV40 DNA to recipient cells (U2OS, SAOS2 and H2052). We determined the 
delivery of SV40 DNA to recipient cells but it was at a very low level of viral copies, indeed we did 
not obtained the viral transfer in all the replicates.  
The entry of viral nucleic acids into recipient cell, involves a series of complex mechanisms, that 
leading to activation of the interferon system. (Dell'Oste et al., 2015; Lo Cigno et al., 2015). In line 
with literature, we analyzed and observed an increase of IFI16, in osteosarcoma cells exposed to 
SV40 positive exosomes. IFI16, would seem to play an important role in the antiviral response, 
because it is able to recognize viral DNA into the cell, playing a restriction role for viral replication. 
(Gariano GR et al., 2012) 
In light of the obtained data and in line with what has been described in the literature, exosomes 
may represent a new transport system for viral content, through which viruses can release their 
nucleic acids in different districts and can evade the immunity system. Furthermore, the release of 
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the exosomal content, would seem to lead a phenotypic cellular change with more aggressive and 
tumorigenic characteristics, due to increased inflammation, invasion and cell proliferation. 
Exosomes contents, appears to be made up of proteins, viral nucleic acids fragments but also 
defective viral molecules. Therefore remains to be seen whether the transfer of viral DNA in the 
recipient cells, may represent a complete replicative unit, triggering a viral infection mechanism. 
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